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Abstract 
Cancer is a leading cause of annual mortality worldwide. Prostate cancer is the second most 
prevalent type of cancer after breast cancer. The conventional treatment options that are 
currently available are not optimal due to their non-specificity as well as treatment often 
failing. Recent advances have turned to nanotechnology as the future of cancer therapy, 
and viral nanoparticles (VNPs) in particular are promising delivery vehicles. VNPs provide a 
protein scaffold that is relatively easy to modify while being biodegradable. Plant viruses 
specifically can be purified with ease at high concentrations and are safe for use in humans. 
Brome mosaic virus (BMV) is an icosahedral virus selected for this study due to its stability 
under a range of experimental conditions, such as pH and temperature, and its robustness 
in chemical conjugation experiments. BMV was also selected for the availability of modifiable 
amino acids on its exterior surface.  
The goal of this project was to engineer BMV as a potential delivery nanoparticle for prostate 
cancer treatments. Wild type BMV was purified from Nicotiana benthamiana and particles 
quantified using transmission electron microscopy as well as dot blots. The virus particles 
were modified by conjugation of two fluorescent molecules, Alexa Fluor-647 and Cy5, to the 
glutamic acid residues on the exterior surface of the BMV capsid. Two peptides, PKRGFQD-
C and SNTRVAP-C, were conjugated to the solvent-exposed lysine residues using three 
SM(PEG)n crosslinkers of different lengths. These peptides respectively target the receptors 
α-2-macroglobulin and GRP78, which are found on the cell surface of androgen-
independent prostate cells. The SM(PEG)24 crosslinker could successfully conjugate the 
peptides. When the fluorescent labeling was performed first, the peptide conjugation was 
unsuccessful. As an alternative, the fluorescent molecule and peptides were both 
conjugated to the lysine residues. The VNPs were assessed in normal and cancerous 
prostate cell lines for non-specific and targeted uptake. This was assessed using 
fluorescence microscopy and flow cytometry. 
The uptake of the VNPs was 75% for PKRGFQD-C and 95% for SNTRVAP-C in the PC3 
cell line, which is indicative of late-stage androgen-independent cancer. The uptake in VCaP 
(early stage androgen-dependent cancer) was lower than for PNT2 (normal prostate cells). 
We consider these results positive as the VNPs will most likely target the androgen-
independent cells. This study demonstrated that BMV, as a candidate VNP, can successfully 
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be modified with a fluorescent molecule and targeting peptide in order to specifically target 
prostate cancer cells.  
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Opsomming 
Kanker is 'n beduidende oorsaak van die jaarlikse sterftesyfer wêreldwyd. Prostaatkanker is 
die tweede mees algemene vorm van kanker, na borskanker. Die konvensionele 
behandeling opsies wat tans beskikbaar is, is nie optimaal weens hul nie-spesifisiteit en die 
behandelings wat dikwels oneffektief is. Onlangse vooruitgang kyk na nanotegnologie as 
die toekoms van kankerterapie, en virale nanopartikels (VNPs) word gesien as ‘n belowende 
afleweringsmiddel. VNPs bied 'n proteïensteier wat relatief maklik is om te modifiseer terwyl 
dit ook bio-afbreekbaar is. Plantvirusse spesifiek kan met gemak gesuiwer word teen 'n hoë 
konsentrasie en is veilig vir menslike gebruik. Brome mosaic virus (BMV) is 'n twintigvlak-
virus wat gekies is vir hierdie studie as gevolg van sy stabiliteit onder 'n verskeidenheid van 
eksperimentele toestande, soos pH en temperatuur, en sy stabiliteit in chemiese konjugasie 
eksperimente. BMV is ook gekies vir die beskikbaarheid van veranderbare aminosure op sy 
buitenste oppervlakte. 
Die doel van hierdie projek was om BMV te modifiseer as 'n potensiële 
afleweringsnanopartikel vir prostaatkankerbehandelings. Wilde tipe BMV is gesuiwer van 
Nicotiana benthamiana en die partikels is gekwantifiseer met behulp van transmissie-
elektronmikroskopie asook immunoklad-tegnieke. Die virusdeeltjies is gewysig deur 
konjugasie van twee fluoresserende molekules, Alexa Fluor-647 en Cy5, aan die 
glutamiensuur aminosuur op die buitenste oppervlak van die BMV kapsied. Twee peptiede, 
PKRGFQD-C en SNTRVAP-C, is gekonjugeer aan die lisien aminosure met behulp van drie 
koppelstukke van verskillende lengtes. Hierdie peptiede teiken onderskeidelik die reseptore 
α-2-macroglobulin en GRP78 wat gevind word op die seloppervlak van androgeen-
onafhanklike prostaatselle. Die SM(PEG)24 koppelstuk het die peptiedes sukkesvol 
gekonjugeer. Alternatiewelik is beide die fluoresserende molekule en peptiede ook 
gekonjugeer aan die lisien aminosure. Wanneer die fluoresserende aanhegting eerste 
uitgevoer was, was die peptied konjugasie onsuksesvol. Beide die fluoresserende molekule 
en peptiede is suksesvol gekonjugeer aan die lisien aminosure. Die VNPs is getoets in 
normale en kanker prostaat sellyne vir nie-spesifieke en geteikende opname met behulp 
van fluoresserende mikroskopie en vloeisitometrie. 
Die opname van die VNPs was 75% vir PKRGFQD-C en 95% vir SNTRVAP-C in die PC3 
sellyn, wat 'n voorbeeld van 'n laat-stadium androgeen-onafhanklike kanker is. Die opname 
in VCaP, 'n voorbeeld van die vroeë stadium androgeen-afhanklike kanker, was minder 
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beduidend as vir PNT2, wat normale prostaat selle is. Ons is van mening dat hierdie 
resultate positief is, want die VNPs sal waarskynlik die androgeen-onafhanklike selle teiken. 
Hierdie studie het getoon dat BMV, as 'n kandidaat VNP, suksesvol gemodifiseer kan word 
met 'n fluoresserende molekule en teikenpeptied om spesifiek prostaatkankerselle te teiken. 
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Chapter 1 
Introduction 
1.1. General introduction 
Cancer is a complex disease diagnosed in millions of people each year and it is a major 
contributor to mortality worldwide. It is comprised of more than 100 distinct diseases, each 
with different risk factors and epidemiology. It can originate in most cells and tissues and 
can be characterized by the uncontrolled proliferation of cells (Stratton et al., 2009). It 
develops through a multistep carcinogenesis process which utilizes multiple cellular 
physiological systems. The disease might start as a localized tumor, but it is prone to 
metastasis in which it quickly spreads throughout the body, which also complicates the 
treatment process (Reichert, 2008; Stratton et al., 2009; Zou, 2005). 
The latest statistics from the GLOBOCAN 2012 project, which is run by the World Health 
Organization’s International Agency for Research on Cancer, indicates that in 2012, 14 
million new cases of cancer were diagnosed worldwide. The number of cancer-related 
deaths were estimated at 8 million people and 32.6 million people were still living with cancer 
after 5 years of being diagnosed, indicating the prevalence of the disease. The cancer types 
with the highest incidence among men are lung cancer, with an incidence of 34.2 per 
100 000, and prostate cancer, with an incidence of 31.1 per 100 000. Breast cancer had the 
highest incidence of all cancer types and in women the incidence was 43.3 per 100 000. 
The second highest cancer type among women was colorectal cancer with an incidence of 
14.3 per 100 000 (Forman and Ferlay, 2014). 
Prostate cancer has the fourth highest incidence1 of all cancers, with an incidence of 31.1 
per 100 000, but the mortality for prostate cancer ranks only eighth with 7.8 per 100 000. 
The prevalence of prostate cancer, however, is a lot higher, ranking second after breast 
cancer with 3.8 million cases (Figure 1.1) (Forman and Ferlay, 2014). These statistics 
suggest that prostate cancer is a major type of cancer that burdens a significant portion of 
society and that research into treatment is critical. 
                                                            
1 Incidence refers to the number of new cases diagnosed whereas prevalence refers to the number of cancer cases 
after 5 years from initial diagnosis. 
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Figure 1.1: Estimated percentage of incidence, mortality and prevalence of cancer in men and women for 
major sites of cancer in 2012 (Adapted from Ferlay et al., (2013)) 
The treatment options that are currently available for cancer include chemotherapy, surgical 
removal of the tumor and radiation (Singhal et al., 2010). However, despite many research 
efforts that have gone into improving these treatments, it still holds a great number of 
limitations. Challenges that are frequently encountered include the non-specific distribution 
of the chemotherapeutic agents throughout the body; the build-up of cytotoxicity due to the 
high concentration of agents in the body, mainly attributed to the large dosages of 
chemotherapy needed due to its untargeted systemic mechanism (Destito et al., 2009); 
difficulty in monitoring the outcome of the response to treatment options; the development 
of multidrug resistance; residual cells that remain after surgical removal and the inability of 
therapeutics to reach the tumor site (Das et al., 2009; Hull et al., 2014; Parveen and Sahoo, 
2008, 2006). These factors signal the need for a more refined approach to the treatment of 
cancer. 
1.2. Aims and objectives 
The aim of this study was to modify an icosahedral plant virus, Brome mosaic virus, for 
targeted delivery to prostate cancer cell lines and fluorescence-based detection. The 
following objectives were set out to achieve the proposed aim:  
 To propagate BMV in a suitable plant host 
 To purify BMV from the plant material 
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 To modify BMV in order to detect it via fluorescence 
 To modify the surface of the viruses with a targeting peptide to target prostate cancer 
cell lines 
 To test the efficiency of these modifications in vitro 
1.3. Chapter layout 
Chapter 1: Introduction 
This chapter gives a general introduction and aims and objectives of the study as well as 
outlines the chapters in the thesis. Research outputs from this study are also highlighted 
here. 
Chapter 2: Literature review 
The literature review gives a thorough summary of the literature on cancer and drug delivery 
nanoparticles. 
Chapter 3: Materials and methods 
The methods that were used in this study are outlined here, as well as the materials and 
equipment used. 
Chapter 4: Results and discussion 
This chapter presents all the results of the study as well as an interpretation of the results. 
Chapter 5: Conclusion 
The last chapter gives concluding remarks on all the findings as well as future prospects of 
the research. 
1.4. Research outputs 
The following conference presentations and posters resulted from this research project. 
1.4.1. Conference proceeding 
Lee, N., Taai, E., Africa, L.D., Steinmetz, N.F., Rybicki, E.P., Burger, J.T., Maree, H.J. 
Engineering of Brome mosaic virus as a drug delivery nanoparticle to prostate cancer cells. 
Presentation of preliminary research presented at the 2nd SA Biomedical Engineering 
Conference, Stellenbosch, South Africa, 22-24 March 2016. 
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1.4.2. Posters 
Lee, N., Africa, L. D., Taai, E., Steinmetz, N. F., Rybicki, E. P., Burger, J. T., Maree, H. J. 
Engineering of Brome mosaic virus as a potential drug delivery nanoparticle to prostate 
cancer cells. Poster of first preliminary research presented at Virology Africa, Cape Town, 
South Africa, 30 November – 3 December 2015. 
Lee, N., Africa, L. D., Taai, E., Steinmetz, N. F., Rybicki, E. P., Burger, J. T., Maree, H. J. 
Engineering of Brome mosaic virus as a potential drug delivery nanoparticle to prostate 
cancer cells. Poster of additional preliminary research presented at the DST-NRF 
Nanotechnology Symposium, Pretoria, South Africa, 27 – 28 June 2016. 
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Chapter 2 
Literature review 
2.1. Cancer 
Cancer is a complex disease that may be caused by a wide variety of factors. The most 
common known factor is carcinogens, such as tobacco smoke and ultraviolet (UV) radiation 
(Bouwman and Jonkers, 2014). These act as mutagens that cause DNA mutations, which 
transform normal human cells into cancerous cells through a multistep process. These 
mutations contribute to the formation of oncogenes, which gain a function that is beneficial 
to the growth of the tumor, and tumor suppressor genes, which lose a function important for 
the control of tumors (Hanahan and Weinberg, 2000). These carcinogens also cause DNA 
damage and the already defective DNA repair signaling pathways aggravate the 
accumulation of DNA damage over time (Bouwman and Jonkers, 2014). 
The cancer genome project was initialized to identify the important genes that are 
susceptible to mutations and thus far 30 tumor suppressive and 100 oncogenes have been 
identified (Futreal et al., 2001). In another census, a total of 291 genes were identified that 
are involved with oncogenesis (Futreal et al., 2004). Oncogenes and tumor suppressor 
genes also contribute to the metabolism of cancer cells by increasing the survival of the 
tumors by enhancing the metabolic pathways. A number of metabolic genes were identified 
that are overexpressed in cancer cells and 16 genes were identified that are specifically 
contributing to tumorigenesis (Scalbert and Romieu, 2014).  
Cancer is also considered a heritable disease, as has been shown by numerous genome-
wide association studies that identified a number of alleles that increase the susceptibility to 
cancer. This is also apparent from cancer types that are more prevalent in families. Some 
cancers can also be more heritable than others, as more alleles are associated with some 
cancer types. These identified alleles allow for initial diagnoses of susceptibility to a certain 
cancer type, providing patients with a potential preventative option (Chanock, 2014). 
2.1.1. Complexity of the disease 
The complexity of the disease is largely due to the vast number of types and subtypes of 
cancer among different populations as a result of the different environments of these regions 
in the world (Hudson, 2014). In 2007 the International Cancer Genome Consortium was 
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founded and they have discovered 50 different tumor types and subtypes within the 25,000 
cancer genomes that were studied (Hudson et al., 2010). This is due to the number of 
mutations that are present in a single tumor (Hudson, 2014) and that each tumor mass can 
present with multiple tumor populations, each with its own unique mutation profile mass 
(Samuel and Hudson, 2013). These tumors also continue to mutate and therefore can 
develop drug resistance over time, which makes this disease even more difficult to treat and 
leads to treatment plans failing after some time (Hudson, 2014). 
Figure 2.1 outlines the main characteristics that are considered to contribute to the 
progression of the disease. In this study our focus will be on the characteristics that 
contribute to the development of the tumor microenvironment (Figure 2.2). The tumor 
microenvironment is a key factor that complicates the treatment process. An important 
characteristic of the microenvironment is the ability of the tumor to form its own blood vessels 
through a process known as angiogenesis. This is initialized once the tumor growth 
increases and it is no longer supplied by the blood vessels. It leads to a hypoxic state in the 
tumors, which prompts an increase in the release of vascular endothelial growth factor 
(VEGF). This is essential for angiogenesis and thereby the tumors are able to create their 
own blood supply, allowing their independent survival (Weis and Cheresh, 2011). 
This microenvironment is also associated with inflammation. Inflammation has been shown 
to be associated with the progression of the disease by contributing to angiogenesis, 
metastasis, cancer cell division and also lowered response to treatment (Colotta et al., 
2009). Inflammation leads to genetic and epigenetic instability, mediated by the reactive 
oxygen species (ROS) that cause DNA damage. Inflammation may also promote the growth 
of the tumor by providing growth factors that may support angiogenesis. The environment 
created by inflammation may also be immunosuppressive, thereby allowing the cancer cells 
to evade the immune system (Grivennikov et al., 2010). This is in large contributed by the 
loss or mutation of cell receptors on the surface of tumors (Schreiber et al., 2011) which may 
lead to the upregulation of receptors that signal the downregulation of the immune response 
(Trinchieri, 2014). 
The tumor microenvironment ultimately leads to a decrease in the effectiveness of the 
different treatments available. The vascular bed becomes hyperpermeable to 
macromolecules and the inflow of extravasated proteinaceous fluid leads to an increase in 
the interstitial pressure inside the cancer cells, which prevents transcapillary transport and 
in turn limits the uptake of therapeutic molecules. It also leads to poor blood flow in tumors 
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and many tumors have varying areas of high or low blood flow. This heterogeneous region 
of blood flow complicates therapy, as it has been shown that hypoxic regions are less 
responsive to radiotherapy, and chemotherapy requires good blood flow to reach the site of 
the tumor. It has also been shown that oxygen deprivation is associated with increased 
metastasis (Langley, 2014). 
 
Figure 2.1: Characteristics of cancer that enable its progression. (A) Six validated and accepted 
characteristics (Hanahan and Weinberg, 2000), (B) Two emerging hallmarks that are currently under study 
and two characteristics that enables the progression of the disease (Hanahan and Weinberg, 2011) 
B 
A 
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Figure 2.2: The tumor microenvironment. Blood endothelial cells (BEC) and lymphatic endothelial cells (LEC) 
are indicated in the healthy cells (Turley et al., 2015) 
A critical factor that makes the disease so devastating is its ability to metastasize. In this 
process some cancer cells will break off and adopt new metamorphic features as well as 
gene expression profiles. They will then migrate to other sites in the body where they will 
invade and proliferate (Thiery et al., 2009). 
2.1.2. Prostate cancer 
Prostate cancer can be classified according to three stages of androgen dependence, of 
which two are illustrated in Figure 2.3. Firstly, early prostate cancer cells are classified as 
androgen dependent, because they rely on the androgen receptor for growth. It requires 5α-
dihydrotestosterone to bind to the androgen receptor, thereby dissociating it from the heat-
shock protein bound to the inactive state. The androgen receptor then translocates to the 
nucleus where it activates the appropriate genes for growth (Debes and Tindall, 2004). 
Prostate cells that respond to androgen but do not require it for growth are termed androgen 
sensitive. This allows for an alternative treatment option by using hormonal treatment for the 
prevention of tumor growth (Paul and Breul, 2000; Rambeaud, 1999; Sciarra et al., 1999). 
Lastly, late stage prostate cancer can be defined as androgen-independent. This type of 
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cancer cell does not require the androgen receptor for growth and may rely on other 
pathways. In many cases the androgen receptor is mutated or amplified and may respond 
to different ligands, other than dihydrotestosterone (Debes and Tindall, 2004).  Androgen-
independence usually occurs when the disease recurs after treatment was initially 
successful (Lara and Meyers, 1999; Laufer et al., 2000), many times accompanied by 
changes in the androgen receptor, either through mutation, amplification or loss (Culig et 
al., 1998; Henshall et al., 2001; Kinoshita et al., 2000; Wang and Uchida, 1997). 
 
Figure 2.3: Androgen-dependent and androgen-independent prostate cancer models (Debes and Tindall, 
2004) 
2.2. Nanotechnology 
A new field that hopes to improve the treatment and diagnosis of cancer is nanotechnology. 
A nanomaterial can be defined as a material with at least one dimension that is less than 
100 nm and exhibits unique properties due to its nanometer size range and its shape. 
Nanotechnology can therefore be defined as the ‘intentional design, characterization, 
production, and application of materials, structures, devices, and systems by controlling their 
size and shape in the nanoscale range (1 to 100 nm)’ (COMA, 2007). Nanomedicine is a 
subset of nanotechnology and this can be defined as the ‘monitoring, repair, construction 
and control of human biological systems at the molecular level, using engineered 
nanodevices and nanostructures’ (Freitas, 1999). 
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2.2.1. Advantages of nanoparticles 
These nanomaterials offer an advantage to conventional cancer treatment as they can 
interact with molecules on the surface of cells as well as inside cells (Destito et al., 2009). 
This is an advantage as it can limit the therapeutics to the site of the cancer cells, thereby 
reducing harmful effects to the surrounding healthy cells (Misra et al., 2010). Certain 
properties of nanotherapeutics allow them to do this: i) the nanoparticles can be designed 
to carry therapeutic drugs to the cells; ii) the nanoparticles can be modified with targeting 
ligands to increase their affinity for cancer cells; iii) multiple drug molecules can be loaded 
onto the nanoparticles to elicit a combinatorial therapeutic effect and iv) nanoparticles can 
bypass drug resistance mechanisms (Acharya et al., 2009). 
Inherent properties of these nanoparticles that make them suitable for cancer therapy are 
their size, payload density, duration of effect and surface properties that allows for targeting. 
The small size allow the nanoparticles to enter the tumors while avoiding extravasation by 
the tumor vasculature through the Enhanced Permeability and Retention (EPR) effect. The 
nanoparticles can carry a large number of molecules on their surface, meaning that 
ultimately a very high concentration of drug molecules can be loaded on a single particle 
(Heidel and Davis, 2011). Many factors, such as the size, surface modifications and particle 
composition, lead to an increase in the duration that these particles are able to circulate in 
the body before being cleared (Alexis et al., 2008; Li and Huang, 2008). This allows for an 
increased dosage of drugs at the cancer cells, leading to more efficient treatment. The last 
property is the ability to modify the surface of the particles in order to improve their 
movement to the cancer cells, either by modifying the surface charge for improved 
circulation or by incorporating a targeting ligand to improve its specificity for the target cell. 
This has been found to enhance endocytosis of these particles by cancer cells, thereby 
limiting treatment to cancer cells only.  
This also has an advantage for multidrug resistance (MDR), which normally severely limits 
the intake and effect of conventional cancer drugs. The microenvironment of cancer cells, 
namely the high interstitial pressure, reduced microvascular pressure and poor vascular 
regions, reduces the ability of drugs reaching the tumor cells. The cancer cells also elicit 
many cellular pathways in order to degrade the cancer drugs. As nanoparticles enter the 
cancer cells by endocytosis, they are able to avoid the MDR mechanisms that are elicited 
at the microenvironment. The drug molecules bound to the nanoparticle will also not be 
degraded as fast as freely circulating molecules (Heidel and Davis, 2011). These 
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advantages suggest that nanoparticles can be utilized for more specific and efficient 
treatment of cancer. 
2.2.2. Types of nanoparticles 
Currently a wide variety of particles are being studied for their functionality as nanoparticles. 
This ranges from synthetic molecules to various biological molecules and relies on different 
distinguishing features depending on the application of the nanoparticle (Figure 2.4). The 
key properties that determine the use of the nanoparticle is its size, the surface properties 
and charge, the shape of the particle as well as its composition, which relates to it being an 
organic or inorganic particle (van Kan-Davelaar et al., 2014). 
 
Figure 2.4: Different types of nanoparticles based on distinguishing properties (van Kan-Davelaar et al., 2014) 
Although inorganic nanoparticles have been well studied and three have been approved for 
phase I clinical trials (Table 2.1), there are some challenges that accompany them. The 
heavy metals may cause toxicity in the body and they have increased difficulty of 
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bioelimination after the therapeutics have been delivered (Destito et al., 2009). This prompts 
an even more refined strategy for the delivery of cancer therapeutics. 
Table 2.1: Inorganic nanoparticles in clinical trials (Bregoli et al., 2016) 
Product name and manufacturer Type of particle Cancer targeted 
Aurimune (CYT-6091) / CytImmune 
Sciences 
PEGylated gold nanoparticle for 
TNF-α delivery 
Solid tumors 
Auroshell, Aurolase / Nanospectra 
Biosciences, Inc. 
Gold-coated silica nanoparticles 
for photothermal therapy 
Head, neck and lung cancer 
BTXR3 / Nanobiotix 
Hafnium oxide nanoparticles for 
radiotherapy 
Squamous cell carcinoma of 
the oral cavity and adult soft 
tissue sarcoma 
2.2.2.1. Organic nanoparticles 
Many organic nanoparticles have been successful in their applications, ranging from phase 
I-III clinical trials and some even received approval from the Food and Drug Administration 
(FDA). The most successful nanoparticles are liposomes, albumin-based nanoparticles, 
micelles and polymeric nanoparticles (Bregoli et al., 2016). This indicates that substantial 
research is done on nanoparticles as the future of cancer treatment and diagnostics. 
Although these organic nanoparticles are very successful in their applications, viral 
nanoparticles surpass them in terms of their inherent properties that make them ideal 
nanocarriers. 
2.3. Viral nanoparticles 
Viruses are evolved to invade a host and deliver genomic cargo into cells (van Kan-Davelaar 
et al., 2014; Yildiz et al., 2011), which means that they are inherently equipped to function 
as a delivery vehicle. Viruses have been extensively studied and characterized on their 
biological, genetic and physical properties. This knowledge enables the manipulation of virus 
particles to suit specific experimental needs (Strable and Finn, 2009).  
There are many advantages that make viruses more ideal than other biological 
nanoparticles, namely i) their wide size range and the characterization of their structures at 
atomic resolution; ii) their monodisperse size and composition of their structures; iii) the wide 
variety of shapes available, each with distinct properties; iv) their constrained interior cavity 
which allows for packaging of molecules on the inside of the particles as well; v) their 
composition may be manipulated by changing the viral genome; vi) their ability of self-
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assembly and polyvalence, which contributes to the stability of the particles; vii) they can be 
produced in large quantities, with relative ease; viii) they are stable at a wide range of 
experimental conditions, such as pH, temperature and chemical modification; and ix) they 
have large surface areas, which allows the conjugation of a large number of molecules per 
particle (Strable and Finn, 2009; van Kan-Davelaar et al., 2014) . 
Because of extensive studies done on viruses, amino acids on the protein capsid of the virus 
can be identified and modified for bioconjugation. The extensive knowledge of the viral 
capsid structure also allows the design of ligands in order to improve the targeting abilities 
of the viral particles. Viruses also have a significant advantage over other nanoparticles due 
to the multiple uniformly distributed sites onto which ligands can be introduced (Destito et 
al., 2009). 
Viruses have been used for vaccines and gene-therapy for many years and some of these 
vaccines are currently used in the clinic, namely the Human papillomavirus (HPV) vaccine 
Gardasil2 (Merck & Co Inc.). Gene therapies based on the Adenovirus, Adeno-associated 
virus, and Lentivirus are currently in clinical trials (Wen et al., 2012b). Viruses derived from 
plants and bacteria are considered the ideal nanoparticles as they are biocompatible, 
biodegradable, non-infectious to mammals, they can be produced in large quantities from 
their respective hosts and they are available in many shapes and sizes (van Kan-Davelaar 
et al., 2014; Yildiz et al., 2011). Viral nanoparticles (VNPs) can also be easily modified, either 
genetically or chemically, and they present with well-ordered, multivalent functional groups 
on their internal and external surfaces (Wen and Steinmetz, 2014). 
Some of the VNPs currently in development are Brome mosaic virus (BMV), Cowpea 
chlorotic mottle virus (CCMV), Cowpea mosaic virus (CPMV), Hibiscus chlorotic ringspot 
virus (HCRSV), Red clover necrotic mottle virus (RCNMV), Potato virus X (PVX), Tobacco 
mosaic virus (TMV), and bacteriophages MS2, Qβ and M13 (Figure 2.5) (Steinmetz, 2010). 
An icosahedral plant virus that has been extensively studied for its use in nanotherapy is 
CPMV (Destito et al., 2009). CPMV is a member of the family Comoviridae with a two-part 
single stranded RNA genome and a non-enveloped viral capsid. The coat proteins of the 
capsid consists of 60 copies of the 23 kDa small subunit and the 41 kDa large subunit which 
fuses to form an icosahedral capsid that surrounds the RNA (Manchester and Steinmetz, 
2009). The icosahedral structure allows for polyvalent display of peptides on the capsid 
                                                            
2 The vaccine contains recombinant VLPs that are assembled from the L1 proteins from the capsid protein of HPV and 
not the whole virus. 
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protein because of its symmetric nature. The crystal structure of CPMV is available at 2.8 Å 
resolution, which allows for designing molecules to be attached to its surface (Chatterji et 
al., 2004). The capsid diameter is 30 nm with a thickness of 1.2 nm. CPMV can be purified 
in large quantities from infected leaves and the particles are stable in a wide range of pH 
and temperature (Manchester and Steinmetz, 2009) and permissive to genetic and chemical 
modifications (Chatterji et al., 2004), making it a suitable candidate for nanoparticle 
applications.  
 
Figure 2.5: VNPs currently in development (Steinmetz, 2010) 
Not only has CPMV extensively been studied for its exterior surface modification, but 
modification of its interior has also been successful. It has been found that CPMV has a 
natural affinity for vimentin which is expressed on the cell-surface of HeLa (cervical cancer), 
HT-29 (colon cancer) and PC3 (prostate cancer) cells to promote internalization of the 
particles. This means that efforts can also be focused on interior modification of CPMV (Wen 
et al., 2012a). In a study by Wen et al., (2012) they demonstrated that the reactive cysteine 
residues on the interior of CPMV can be utilized to attach fluorescent dye molecules. They 
also produced a CPMV devoid of any RNA, which they found to increase the affinity for dye 
molecules. 
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2.4. Brome mosaic virus 
Another plant virus with great potential as a VNP is BMV. BMV is a T=3 icosahedral shaped 
virus from the family Bromoviridae and genus Bromovirus (Fauquet et al., 2005). It has a 
diameter of 28 nm at a pH below 6 (Lucas et al., 2001). It has a molecular weight of                
4.6 x 106 Da and a coat protein size of 20 kDa (Bockstahler and Kaesberg, 1962). The coat 
protein consists of 189 amino acids and a highly positively charged amino-terminus (Lucas 
et al., 2002).The crystal structure has been resolved at 3.4 Å resolution (Lucas et al., 2002). 
The virus is comprised of 180 subunits in its coat protein which assumes an equal number 
of either A, B or C conformation (Figure 2.6). It has a multipartite single-stranded RNA 
genome, consisting of RNA1 (3.2 kb), RNA2 (2.8 kb), RNA3 (2.1 kb) and a small RNA4 (800 
bp) that encodes only for the coat protein and is found packaged together with RNA3 
(Ahlquist et al., 1990). 
 
Figure 2.6: Structure of BMV representing the T=3 organization of the 180 coat proteins 
BMV has been studied extensively for its ability to disassemble and reassemble into empty 
capsids. This has been utilized to encapsulate a number of synthetic molecules, such as 
gold nanoparticles, iron oxide cores and quantum dots, and fluorescent molecules (Daniel 
et al., 2010; Dixit et al., 2006; Huang et al., 2011, 2007; Jung et al., 2011; Sun et al., 2007). 
Thus far BMV has not been thoroughly explored for its use in bioconjugation. Yildiz et al. 
(2012) demonstrated the ability of cysteine-BMV (cBMV) mutants to conjugate 
OregonGreen 488 to the introduced cysteine residues using thiol-maleimide chemistry. 
cBMV was also successfully conjugated with PEG2000, Transferrin, Doxorubicin and R5-
peptides. OregonGreen 488 was also successfully conjugated to the lysine residues of 
cBMV and PEG2000 to the cysteine residues (Wen et al., 2012a). Thus far native BMV has 
not been used with bioconjugation chemistries other than the addition of a fluorophore to 
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the lysine residues. This study will be a novel approach, since it is the first time that native 
BMV will be modified as a VNP with a targeting peptide. 
2.5. Production of VNPs 
VNPs can be produced from their natural hosts in gram quantities. The purified VNPs can 
then be modified for the desired application by means of three different methods, namely 
genetic engineering, chemical bioconjugation and self-assembly (Figure 2.7).  
 
Figure 2.7: Different methods for production of VNPs. (A) Genetic engineering, (B) Chemical bioconjugation, 
(C) Self-assembly. Adapted from Yildiz et al. (2011). 
A B 
A B 
C 
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In genetic engineering amino acids can be inserted into the virus genome that can serve as 
targets during chemical modification (Yildiz et al., 2011). This is commonly used to add 
cysteine residues to CPMV (Wang et al., 2002). Peptides can also be inserted as well as 
peptide-based affinity tags (Yildiz et al., 2011). In chemical conjugation specific 
bioconjugation methods are used to functionalize the amino acids on the virus capsid to 
introduce molecules of choice. Encapsulation makes use of the ability of viruses to swell 
and encapsulate a molecule or to disassemble and reassemble around the molecule of 
choice. These two methods are used to introduce a variety of molecules (Figure 2.8) that 
can be used in a variety of applications (Yildiz et al., 2011). 
 
Figure 2.8: Variety of molecules that can be conjugated or encapsulated into VNPs for different applications 
(Singh et al., 2006). 
2.5.1. Targeting mechanism 
VNPs can be internalized into cells by two different mechanisms, passive targeting and 
active targeting (Figure 2.9). Passive targeting refers to the accumulation of nanoparticles 
to the desired site by making use of the unique properties of the nanoparticles, such as their 
size, and the microenvironment of the tumor site. Nanoparticles are able to use the 
vascularized areas of the tumor site and the higher metabolic rate of cancer cells to rapidly 
accumulate on the inside of the tumor. This is also known as the enhanced permeability and 
retention (EPR) effect in which the tumor vasculature is composed of various gaps along 
the endothelium. This allows the internalization of macromolecules up to 400 nm in diameter. 
Active targeting makes use of a ligand attached to the nanoparticle that is specific to a 
receptor presented on the cancer cells. It is therefore important that the receptor is only 
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expressed on the tumor and not on healthy cells as this will decrease the targeting ability of 
the particles. Upon binding to the tumor receptor, the nanoparticle can be internalized by 
endocytosis. This method of targeting further increases the effectiveness of treatment and 
also lowers the toxicity to healthy cells (Bamrungsap et al., 2012; Misra et al., 2010) 
 
Figure 2.9: Passive and active targeting of nanoparticles to cancer cells. (A) Passive targeting, (B) Active 
targeting (Bamrungsap et al., 2012) 
2.5.2. Conjugation of a fluorescent molecule 
A fluorescent molecule is added to the VNP in order to track its movement in vitro. This can 
also be used as an imaging agent in vivo, but for this study it will be used to validate the 
internalization of the VNPs in vitro. 
BMV has 8 solvent exposed glutamic acid residues per coat protein, as determined by 
VIPERdb (Carrillo-Tripp et al., 2009): Glu76 and Glu160 in the A subunit and Glu55, Glu76 
and Glu160 in both the B and C subunits. The reactivity of these amino acids is unknown as 
it has never been used for bioconjugation. The reason for choosing the glutamic acids is 
that they are readily available on the exterior of the coat protein of BMV. Additionally, the 
glutamic acids can easily be modified using the 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) coupling reaction and the copper(I)-catalyzed 
alkyne-azide cycloaddition (CuAAC), also known as “click” chemistry. 
The EDC coupling is used to conjugate an alkyne to the carboxylate group of the glutamic 
acids by means of an EDC activated propargylamine. The alkyne is then functionalized using 
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the CuAAC reaction to attach a fluorescent molecule containing a terminal azide (Bruckman 
and Steinmetz, 2014) (Figure 2.10). 
 
Figure 2.10: Conjugation of a fluorophore to the glutamic acids on the exterior coat protein of BMV. (A) EDC 
reaction to attach an alkyne to the glutamic acids, (B) CuAAC reaction to functionalize the alkyne with an 
azide-containing fluorophore (Bruckman and Steinmetz, 2014) 
2.5.3. Conjugation of a targeting peptide 
Finally a targeting peptide is required for the VNPs to target the cancer cells. Mandelin et al. 
(2015) identified two novel peptides, PKRGFQD and SNTRVAP, which are specific for the 
receptors on androgen-independent prostate cancer. PKRGFQD has been shown to 
specifically target the α-2-macroglobulin receptor and SNTRVAP for the 78-kDa glucose-
regulated protein (GRP78) receptor. These receptors are specifically upregulated in 
androgen-independent cell lines. 
Androgen deprivation is one of the main treatment options currently used for metastatic 
prostate cancer, but the limitation is that many metastatic cancers develop androgen-
independence. This makes this treatment ineffective and the tumors give rise to osteoblastic 
bone and soft tissue metastasis, which ultimately can be fatal (Mandelin et al., 2015). 
Therefore the targeting peptides will aid in the delivery of nanoparticles to androgen-
independent cancer cells to improve the treatment thereof. The peptides have not been 
studied for their use as targeting ligands for nanoparticles and therefore this will be a novel 
approach in this study. 
BMV has previously been shown to have 180 reactive lysine residues (Wen et al., 2012a) 
that can be used to successfully conjugate molecules using NHS ester chemistry. An amine-
to-sulfhydryl crosslinker with soluble polyethylene glycol (PEG) spacer arms can be used to 
achieve this. The NHS group on the one end of the crosslinker will conjugate to the amine 
A 
B 
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group on the lysine to create an amide bond with the release of a free NHS compound 
(Figure 2.11) (Thermo Scientific, 2012). 
 
Figure 2.11: NHS ester reaction representing the conjugation of the amine on the crosslinker to the amine of 
the lysine on the BMV coat protein. The NHS ester reagent represents the free amine on the crosslinker and 
the primary amine of protein represents the free amine group on the lysine residue (Thermo Scientific, 2012) 
The peptides were synthesized with a terminal cysteine that will be conjugated to the 
maleimide group on the crosslinker using maleimide chemistries. In this reaction the 
sulfhydryl on the cysteine will conjugate to the maleimide group on the crosslinker to create 
a thioether bond (Figure 2.12) (Thermo Scientific, 2012). 
Crosslinkers of different lengths will be utilized to assess the efficiency of conjugation with 
the varying distance that the peptide is conjugated to the lysine on the coat protein. The 
principle is that certain crosslinkers might not create sufficient space for the peptide to bind 
as there might be interference from surrounding amino acids in the coat protein. 
 
Figure 2.12: Maleimide reaction representing the conjugation of the sulfhydryl on the peptide to the maleimide 
on the crosslinker (Thermo Scientific, 2012) 
2.6. Conclusion 
Cancer is a devastating disease that affects the lives of millions of people each year. The 
current treatment options that are available are not optimal and there is a need for a more 
refined treatment. Nanomedicine offers the opportunity for a treatment that can be tailored 
and that can specifically target cancer cells, without leading to damage to healthy cells, as 
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is the case with conventional treatments. Various nanoparticles have been developed, both 
organic and inorganic nanoparticles, but currently viruses are considered the ideal 
nanocarrier. 
VNPs can be tailored for any specific application and the many shapes and sizes of viruses 
that are available makes them suitable for a desired application. Brome mosaic virus is an 
icosahedral virus that has been extensively studied for its reassembling ability to 
encapsulate molecules, but not for bioconjugation. This study will be novel in its regard to 
bioconjugate native BMV for the targeting of prostate cancer. 
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Chapter 3 
Materials and methods 
3.1. Diagnostics 
Plant material infected with Brome mosaic virus (BMV) was received from the Department 
of Agriculture, Forestry and Fisheries (DAFF). The presence of BMV in this plant material 
was confirmed by means of reverse transcriptase polymerase chain reaction (RT-PCR) and 
a dot blot. 
3.1.1. RT-PCR 
Primers were designed for the coat protein gene located on RNA 3 (Accession number 
X58459.1) using the Oligo Explorer (v 1.1.2) software (Kuulasma, 2000). The characteristics 
of the primers are summarized in Table 3.1. 
Table 3.1: Primers used for diagnostics of BMV 
Primer Sequence Tm (°C) Amplicon size 
BMV_CP_F 5’-CAGGAACTGGTAAGATGACTC-3’ 52.3 
521 bp  
BMV_CP_R 5’-CCTTACGTGCTCAACTTCTAG-3’ 52.8 
3.1.1.1. Crude extraction of viral RNA 
Initially, an optimized one-step RT-PCR was used to screen for BMV. First, 0.3 g of leaf 
tissue was ground in 2 ml extraction buffer (2 % [w/v] PVP-40, 0.2 % [w/v] bovine serum 
albumin [BSA], 0.05 % [v/v] Tween20, 1 % [w/v] Na2S2O5, in carbonate buffer [0.159 % (w/v) 
Na2CO3, 0.293 % (w/v) NaHCO3], pH 9.6). Of this homogenate, 8 µl was added to 50 µl 
GES buffer (0.1 M glycine NaOH [pH 9], 0.05 M NaCl, 0.001 M EDTA, 0.5 % [v/v] Triton X-
100) and incubated at 95 °C for 10 minutes. It was then incubated on ice for 5 minutes, after 
which 2 µl of the reaction was used in the RT-PCR.  
3.1.1.2. One-step RT-PCR 
The RT-PCR reaction mix contained 1 x KAPA Taq Buffer A (KAPA Biosystems), 0.625 µM 
each of forward and reverse primer (IDT), 0.2 mM dNTP mix (Fermentas), 5 mM dithiothreitol 
(DTT), 10 U Avian Myeloblastosis Virus (AMV) reverse transcriptase (RT) (Fermentas), 1 U 
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KAPA Taq (KAPA Biosystems), 2.5 µl 5 x Cresol loading dye (30 % [w/v] sucrose; 125 mg 
cresol red dye) and was diluted to a final volume of 25 µl using Milli-Q® water.  
The reaction was performed using the 2720 thermal cycler (Applied Biosystems) and cycling 
conditions included an initial step at 48 °C for 30 minutes, followed by 35 cycles of 94 °C for 
30 seconds, annealing at 55 °C for 30 seconds and elongation at 72 °C for 30 seconds. The 
final extension was at 72 °C for 7 minutes.  
The PCR products were resolved on a 1.5 % (w/v) TAE-agarose gel (2 M Tris, 1 M glacial 
acetic acid, 0.05 M Na2EDTA, pH 8), stained with ethidium bromide (EtBr), at 110 V for 40 
minutes. The gel was visualized using a Bio-Rad Gel Doc™ XR+ Molecular Imager®. 
3.1.1.3. RNA extraction 
RNA was extracted for a two-step RT-PCR using an adapted Cetyltrimethylammonium 
bromide (CTAB) extraction protocol (2 % [w/v] CTAB, 2.5 % [w/v] PVP-40, 100 mM Tris-
HCL [pH 8], 2 M NaCl, 25 mM EDTA [pH 8] and 3 % [v/v] β-mercaptoethanol) (White et al., 
2008). The extracted RNA was quantified on a NanoDrop™ 2000 spectrophotometer 
(Thermo Scientific). 
3.1.1.4. Two-step RT-PCR 
The extracted RNA was subjected to cDNA synthesis by mixing 250 ng of RNA, 0.25 µl of 
the reverse primer (IDT) to a final volume of 10 µl with Milli-Q® water. The mix was incubated 
at 65 °C for 5 minutes and subsequently on ice for 2 minutes. The reaction mix contained 
5x AMV-RT buffer (Fermentas), 10 mM dNTP mix (Fermentas), 10 U AMV-RT and 10 µl of 
the previously incubated reaction was diluted to a final volume of 20 µl using Milli-Q® water. 
The reaction was performed using the 2720 thermal cycler (Applied Biosystems) and 
included an initial incubation at 50 °C for 30 minutes, followed by an incubation at 85 °C for 
5 minutes. 
The cDNA was used in a PCR with the reaction mix consisting of 2.5 µl cDNA, 20 µM forward 
primer (IDT), 20 µM reverse primer (IDT), 10 mM dNTP mix (Fermentas), 1 U KAPA Taq 
(KAPA Biosystems), 1 x KAPA Taq Buffer A (KAPA Biosystems), 2.5 µl 5 x Cresol loading 
dye (30 % [w/v] sucrose; 125 mg cresol red dye) and diluted to a final volume of 25 µl using 
Milli-Q® water. The cycling conditions included an initial denaturing step at 95 °C for 5 
minutes, followed by 35 cycles of 95 °C for 30 seconds, 50 °C for 30 seconds and 72 °C for 
30 seconds, and a final elongation at 72 °C for 7 minutes. 
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The PCR products were resolved on a 1.5 % (w/v) TAE-agarose gel stained with EtBr, at 
110 V for 40 minutes. 
3.1.2. Dot-blot 
The infected material was screened for the presence BMV by means of a dot-blot by using 
BMV-specific antiserum, obtained from the Biopharming Research Unit (BRU) at the 
University of Cape Town (UCT). 
First, the nitrocellulose membrane was equilibrated by dipping it in methanol for 2 seconds, 
reverse osmosis (RO) water for 5 minutes and phosphate buffered saline (PBS) (0.8 % [w/v] 
NaCl, 0.02 % [w/v] KCl, 0.144 % [w/v] Na2HPO4, 0.024 % [w/v] KH2PO4, pH 7.5) with         
0.05 % (v/v) Tween20 added (PBS-T), for 5 minutes. 2 µl of the sample was dried on the 
membrane and the membrane was subsequently incubated in blocking buffer (PBS-T, 5 % 
[w/v] milk powder) for 2 hours on a shaker at 37 °C. The membrane was washed with PBS-
T for 5 minutes, repeated three times and then incubated with the BMV antiserum (1:100 
dilution for a stock of 50 mg/ml, PBS-T, 5 % [w/v] milk powder) for 1 hour at room 
temperature. The wash step was repeated and the membrane incubated with the anti-rabbit 
IgG alkaline phosphatase conjugate (Sigma-Aldrich®) for 1 hour at room temperature 
(1:30,000 dilution, PBS-T, 5 % [w/v] milk powder). The wash step was repeated and the 
membrane was incubated with 10 ml alkaline phosphatase (AP) (100 mM Tris [pH 9.5],     
100 mM NaCl, 5 M MgCl2), 66 µl NBT (75 mg/ml stock) and 33 µl BCIP (50 mg/ml stock) in 
the dark until a color change was observed. 
3.2. Virus Purification 
3.2.1. Inoculation and propagation 
Nicotiana benthamiana was seeded and grown under standard greenhouse conditions for 6 
weeks. BMV-infected source material was homogenized in inoculation buffer (30 mM 
K2HPO4, 50 mM glycine, 1 % [w/v] celite, 1 % [v/v] bentonite, pH 9.2) and the inoculum was 
rubbed on 4 leaves per plant. The virus was allowed to propagate for three weeks after 
which the leaf material was harvested and stored at -80 °C. 
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3.2.2. Purification 
3.2.2.1. Purification method 1 
BMV was purified from infected leaf material using a protocol adapted from Bujarski (1998). 
Unless otherwise specified, all centrifugation steps were performed at 10,000 x g using the 
Beckman Coulter™ Allegra™ X-22R Centrifuge (F0850 rotor) at 4 °C. First, the frozen leaf 
material was ground in a chilled mortar and pestle in 1 ml extraction buffer (0.5 M sodium 
acetate, 0.01 M acetic acid, 0.01 M MgCl2, pH 5.2) per gram of tissue. The homogenate was 
emulsified with 0.2 ml chloroform per gram of tissue and subjected to centrifugation at    
5,000 x g for 5 minutes. The supernatant was filtered through course filter paper and 
incubated on ice for 30 minutes with one-third volume 30 % (w/v) polyethylene glycol (PEG) 
8000. The precipitate was collected by centrifugation for 10 minutes and the pellet dissolved 
in 0.2 ml storage buffer (0.05 M sodium acetate, 0.01 M acetic acid, 1 mM Na2EDTA, 1 mM 
MgCl2, pH 5.2) per gram of tissue. The solution was emulsified with 0.4 ml chloroform per 1 
ml of the solution and subjected to centrifugation for 5 minutes. The pellet was resuspended 
in 0.2 ml storage buffer per gram of tissue on ice overnight. The resuspended solution was 
centrifuged for 10 minutes and the supernatant subsequently subjected to two rounds of 
differential centrifugation using a Beckman Coulter Optima L-100 XP ultracentrifuge (Type 
35 rotor). First, the sample was centrifuged at 100,000 x g for 2 hours, then the pellet was 
resuspended in the storage buffer. Finally, this was centrifuged at 30,000 x g for 10 minutes. 
The supernatant was subjected to another round of differential centrifugation, and the virus 
stored at -80 °C. 
3.2.2.2. Purification method 2 
A second protocol, from Michel et al. (2004), was used to purify BMV from infected leaf 
material. All steps were carried out at 4 °C and centrifugation steps were performed at 
10,000 x g using the Beckman Coulter™ Allegra™ X-22R Centrifuge (F0850 rotor). Frozen 
leaf material was homogenized in grinding buffer (0.2 M sodium acetate, 0.01 M Na2EDTA, 
pH 4.8) in a 1:2 ratio using a blender. The homogenate was squeezed through three layers 
of cheesecloth and subjected to centrifugation for 15 minutes. The supernatant was stirred 
with 10 % (w/v) PEG 8000 overnight after which it was centrifuged for 10 minutes. The pellet 
was resuspended in storage buffer (0.1 M sodium acetate, 0.001 M Na2EDTA, pH 5.2), at 
one-tenth of the initial buffer used, and subjected to centrifugation for 10 minutes. The 
supernatant was stirred with 15 % (w/v) PEG 8000 for 2 hours and subsequently centrifuged 
for 10 minutes. The pellet was resuspended in 1 ml storage buffer, centrifuged for 10 minutes 
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and the supernatant collected. The purified virus were further purified by ultracentrifugation 
at 160,000 x g for 2.5 hours using the Beckman Coulter Optima L-100 XP ultracentrifuge 
(Type 70Ti rotor). The samples were layered on a 40 % (w/v) sucrose cushion prior to 
centrifugation. 
3.3. Bioconjugation 
3.3.1. Fluorescent labelling 
The glutamic acid residues on the exterior surface of the BMV coat protein were modified 
using the 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and copper(I)-catalyzed 
alkyne-azide cycloaddition (CuAAC), also known as “click”, chemistries. The protocol for this 
reaction was adapted from Bruckman and Steinmetz (2014). 
For all reactions the following formula was used to calculate the volume (in µl) of reagents 
to add for the number of molecular equivalents in the reaction: 
(
𝑉𝑁𝑃
𝑀𝑊 𝑉𝑁𝑃 × # 𝐶𝑃 𝑝𝑒𝑟 𝑉𝑁𝑃) × 𝐸𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡𝑠
𝑆𝑡𝑜𝑐𝑘 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
× 1000 
In the formula, 𝑉𝑁𝑃 represents the concentration of the virus used in the reaction; for all 
reactions a concentration of 2 mg/ml was used. The molecular weight is given by 𝑀𝑊 𝑉𝑁𝑃 
while # 𝐶𝑃 𝑝𝑒𝑟 𝑉𝑁𝑃 is the number of coat protein subunits of the virus. For BMV this is         
4.6 x 106 g/mol and 180 respectively. 𝐸𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡𝑠 is the number of molecular equivalents 
(eq) of the reagents to ensure a great enough excess for the reaction to occur. This value 
differs for each reagent. 𝑆𝑡𝑜𝑐𝑘 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 represents the concentration of the stock 
solution of the reagents to be added to the reaction. 
3.3.1.1. EDC reaction 
The EDC reaction was utilized in order to modify the glutamic acid residues on the surface 
of the BMV coat protein in order to produce alkyne-BMV particles. These will subsequently 
be used to conjugate the fluorescent molecules. 
BMV particles (at a concentration of 2 mg/ml) was added to 0.1 M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer (pH 7.4) and mixed by vortexing for 2 
seconds. The solution was then incubated for 24 hours at room temperature while agitating 
with 120 eq propargylamine (0.1 M stock) (Sigma-Aldrich®), 30 eq EDC (0.1 M stock) 
(Sigma-Aldrich®) and 3 mg Hydroxybenzotriazole (HOBt) (Sigma-Aldrich®) in a final volume 
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of 1 ml. The EDC was added at the start of the reaction, another 30 eq after 6 hours and a 
final 30 eq after incubating for 18 hours, equating to a final amount of 90 eq in the reaction. 
The modified particles were purified by ultracentrifugation at 160,000 x g for 2.5 hours using 
the Beckman Coulter Optima L-100 XP ultracentrifuge (Type 70Ti rotor). The samples were 
layered on a 40 % (w/v) sucrose cushion prior to centrifugation. The pellet was resuspended 
in a minimal volume of sodium acetate buffer (0.1 M sodium acetate, 0.001 M Na2EDTA, pH 
5.2), where an approximate of 50 µl buffer per 1 ml reaction was used. These were the 
ultracentrifugation conditions used for all subsequent reactions. 
3.3.1.2. CuAAC reaction 
The CuAAC reaction was used to conjugate an azide-fluorophore to the alkyne-BMV in order 
to produce a fluorescently labelled VNP. All subsequent reactions were performed in the 
dark as the fluorescent molecule is light sensitive. 
Alkyne-BMV (at a concentration of 2 mg/ml) was added to cold sodium acetate buffer and 
mixed by vortexing for 2 seconds. The solution was incubated on ice for 30 minutes with      
5 eq Cy5-azide (0.01 M stock) (Sigma-Aldrich®), 10 µl aminoguanidine (0.2 M stock) (Sigma-
Aldrich®), 10 µl ascorbic acid (0.2 M stock) (Fluka Analytical), 10 µl copper (II) sulfate 
pentahydrate (0.1 M stock) (Sigma-Aldrich®) and 10 % (v/v) dimethyl sulfoxide (DMSO) in a 
final volume of 1 ml. The reaction was inactivated by the addition of 10 µl EDTA (0.5 M 
stock) and incubated on ice for 5 minutes. The samples were subjected to centrifugation at 
14 000 x g for 5 minutes using the Eppendorf Centrifuge 5415R (F45-24-11 rotor) to 
separate unbound fluorescent molecules. The modified particles were purified by 
ultracentrifugation. 
The following changes were made to the aforementioned protocols in order to optimize the 
outcome of the conjugation. Initially two different EDC reactions were performed, one using 
sodium acetate as the buffer and the other using a HEPES buffer as suggested by the 
protocol, due to BMV not being stable at a pH above 6. For the CuAAC reaction a final 
volume of 500 µl instead of 1 ml was used for the reaction that utilized the sodium acetate 
buffer. For this reaction Alexa Fluor® 647 (Molecular Probes®) was used as the fluorescent 
molecule. 
Three different reactions were performed, one with a final reaction volume of 3 ml instead 
of 1 ml, ten 1 ml reactions and one with a final reaction volume of 10 ml. The pellet for the 3 
ml reaction was resuspended in 50 µl and the other two reactions in 100 µl sodium acetate 
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buffer. As before, Alexa Fluor® 647 (Molecular Probes®) was used as the fluorescent 
molecule. 
The EDC reaction was optimized by attempting different conditions for the reactions. 
Reaction 1 used the normal protocol as described previously. In reaction 2 the HOBt was 
omitted. In reaction 3 the HOBt was omitted and EDC was added only at 6 hours and at 18 
hours. In reaction 4 a lower stock concentration of the virus was used and hence a higher 
volume of virus was added to the reaction. In reaction 5 the lower stock concentration of the 
virus was added and the HOBt was omitted. In reaction 6 the HOBt was omitted and only 
one addition of EDC was made at the beginning of the reaction. 
Purified BMV obtained from the Biopharming Research Unit (BRU) at the University of Cape 
Town (UCT) was used with our purified BMV to test the viability of the different purified 
stocks. Two different BMV stocks from BRU was used with one of our own stocks. 
The EDC reaction was again performed in a final volume of 10 ml. 
3.3.2. Peptide conjugation 
The lysine residues on the exterior surface of the BMV coat protein was modified for 
conjugation of the targeting peptides, PKRGFQD-C (which will further on be referred to as 
Peptide 1) and SNTRVAP-C (which will further on be referred to as Peptide 2). Crosslinker 
molecules, with an amine group (-NH2) on the one end and a sulfhydryl group (-SH) on the 
other end, was used to conjugate the peptide to the VNP. During this reaction the amine 
group was conjugated to the lysine residues, while the sulfhydryl group on the peptide was 
conjugated to the sulfhydryl group on the crosslinker. The protocol for this reaction was 
adapted from Chariou et al. (2015). For calculating the volume of the peptides, to add to the 
reaction, the previous formula was adjusted to the following: 
(
𝑉𝑁𝑃
𝑀𝑊 𝑉𝑁𝑃 × # 𝐶𝑃 𝑝𝑒𝑟 𝑉𝑁𝑃) × 𝐸𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡𝑠
𝑆𝑡𝑜𝑐𝑘 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
 
The Cy5-labelled BMV (at a concentration of 2 mg/ml) was added to sodium phosphate 
buffer (0.1 M, pH 7.4) and mixed by vortexing. The reaction was incubated with 6 eq      
(0.250 M stock) (succinimidyl-[(N-maleimidopropionamido)-diethyleneglycol] ester) 
SM(PEG)n crosslinkers (Thermo Scientific) and 10 % (v/v) DMSO in a final volume of 1 ml 
for 2 hours on ice. Three different lengths of crosslinkers were used, namely SM(PEG)8, 
SM(PEG)12 and SM(PEG)24. After the incubation, 6 eq of the peptide (10 x 10-6 M stock,    
0.1 % [v/v] trifluoroacetic anhydride [TFAA] in MilliQ® water) (GL Biochem Shanghai Ltd) 
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was added and incubated overnight at 4 °C (this was later amended to room temperature 
on a shaker). The modified particles were subjected to ultracentrifugation. 
The following changes were made to the aforementioned protocol in order to optimize the 
outcome of the conjugation. The reaction was performed on native, unconjugated BMV to 
test whether the peptides bind to BMV. Both Peptide 1 and Peptide 2 were used with 
crosslinker SM(PEG)24. The reaction with the native, unconjugated BMV was repeated with 
crosslinkers SM(PEG)8 and SM(PEG)12 and both peptides to test whether the peptides bind 
to BMV. 
As an alternative, the conjugation process was reversed, i.e. the peptide conjugation was 
performed first and the peptide-conjugated virus was subsequently conjugated with the 
fluorescent molecule. 
During the peptide conjugation, the crosslinker was first incubated with the peptide for 2 
hours on ice and the Cy5-BMV subsequently added and incubated overnight at room 
temperature while agitating. 
3.3.3. Alternative conjugation method 
An alternative conjugation method was used to conjugate both the peptide and the 
fluorescent molecule to the lysine residues (Chariou et al., 2015) on the coat protein of BMV. 
BMV (at a concentration of 2 mg/ml) was incubated with 2 eq Cy™5 NHS Ester (GE 
Healthcare UK Limited), 2 eq SM(PEG)24 and 10 % (v/v) DMSO in 100 mM potassium 
phosphate buffer (pH 7) in a final volume of 1 ml for 2 hours at room temperature while 
agitating. The modified BMV was subjected to ultracentrifugation. The pellet was 
resuspended in 100 mM potassium phosphate buffer and incubated with 20 eq Peptide 1 
and Peptide 2 in a final volume of 1 ml overnight at room temperature while agitating. The 
modified BMV was purified by ultracentrifugation and the pellet resuspended in sodium 
acetate buffer.  
3.4. Quality control 
The modified VNPs were subjected to a variety of quality control steps to verify whether the 
conjugation methods were successful and have produced particles of high quality, as 
assessed by the purity and integrity of the particles. 
3.4.1. Electron microscopy 
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Samples were visualized using electron microscopy to ensure that the particles were intact 
before proceeding with subsequent steps. 20 µl of the sample (between 0.5 and 1 mg/ml) 
was incubated on a carbon film 200 mesh copper grid (Electron Microscopy Sciences) for 
10 minutes. The grids were washed with two drops of Milli-Q® water and dried on filter paper. 
The samples were subsequently stained with 2 % (w/v) uranyl acetate for 10 minutes and 
blotted dry on filter paper. The grids were allowed to dry in a desiccator (Nalgene™) before 
visualization. 
3.4.1.1. Scanning transmission electron microscope (STEM) 
The samples were visualized using the Zeiss MERLIN Field Emission Scanning Electron 
Microscope (FE-SEM) at the Electron Microbeam Unit of the Central Analytical Facility 
(CAF) at Stellenbosch University for initial analysis before proceeding with subsequent 
steps. 
A Zeiss five-diode Scanning Transmission Electron Detector (Zeiss aSTEMA Detector) and 
Zeiss Smart SEM software were used to generate the STEM images. The beam conditions 
during analysis on the Zeiss MERLIN FE-SEM were set to 20 kV accelerating voltage,       
250 pA probe current and a working distance of 4 mm. The images were acquired by using 
the orientated dark field (ODF) bright fields (BF) mode with the S1 and S2 diodes activated 
and the S3 diode inverted. 
3.4.1.2. Transmission electron microscope (TEM) 
Some of the samples were submitted to the Electron Microscope Unit (EMU) at The Centre 
for Imaging and Analysis at the University of Cape Town (UCT). The negatively stained 
samples were visualized using a Tecnai F20 FEGTEM operating at 200 kV and the images 
were obtained using a Gatan US4000 digital camera controlled by the Digital Micrograph 
software suite. 
3.4.2. Spectrophotometry 
The samples were analyzed using the Nanodrop 2000 spectrophotometer (Thermo 
Scientific) to assess the concentration and purity of the particles after conjugation. The 
absorbance at 260 nm was used to calculate the concentration of the samples and the 
260/280 ratio indicated the level of purity. The number of fluorescent molecules conjugated 
to the particles could also be calculated by using the absorbance of the fluorescent 
molecules at 647 nm as well as the absorbance of the virus particles at 260 nm. The 
following formula was used to calculate the number of bound fluorescent molecules: 
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𝐴 647
𝜀 𝑓𝑙𝑢𝑜𝑟𝑜𝑝ℎ𝑜𝑟𝑒
×
𝑀𝑊 𝑉𝑁𝑃
𝐴 260
𝜀 𝑉𝑁𝑃
 
Here, 𝐴 647 represents the absorbance of the fluorescent molecule and 𝐴 260 the 
absorbance of the virus particle. The 𝜀 𝑓𝑙𝑢𝑜𝑟𝑜𝑝ℎ𝑜𝑟𝑒 represents the extinction coefficient of 
the fluorescent molecules. For the Alexa Fluor® 647 fluorophore this value is 239,000 and 
for the Cy5-azide this value is 250,000. The 𝜀 𝑉𝑁𝑃 represents the extinction coefficient of 
the virus particle, which for BMV is 5.15, and the 𝑀𝑊 𝑉𝑁𝑃 represents the molecular weight 
of the virus particle. For BMV this value is 4.6 x 106 g/mol. 
3.4.3. SDS-PAGE 
The modified BMV particles were subjected to polyacrylamide gel electrophoresis to assess 
whether the peptides were successfully conjugated to the particles. An amount of between 
20 and 50 µg sample was loaded into each well, in the case where enough sample was 
obtained during the conjugation process. In the case where less than 20 µg was available 
after conjugation, a maximum of 37.5 µl was used. The samples were first denatured in a 
4x Laemmli sample buffer (Bio-Rad) in a ratio of 1:4 by incubating for 5 minutes at 95 °C. 
The samples were loaded onto a 4-15 % Mini-PROTEAN® TGX™ Precast Gel (Bio-Rad) 
along with a Precision Plus Protein™ Standard (Bio-Rad). The samples were allowed to 
separate on the gel for 1 hour at 120 V. The gel was visualized using the Bio-Rad Gel Doc™ 
XR+ Molecular Imager® and the images were analyzed using the Image Lab™ Software 
(Image Lab, 2014). 
3.4.4. MALDI-TOF MS 
The modified particles were assessed by means of Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) to verify whether 
the peptides were conjugated to the particles. The samples were analyzed at the Proteomics 
Research & Services Unit in the Department of Biotechnology at the University of the 
Western Cape (UWC). All the samples were prepared according to the protocol described 
by Bruckman and Steinmetz (2014) prior to analysis. 
The measurements were performed using an UltrafleXtreme MALDI ToF/ToF system 
(Bruker Daltonics) with instrument control through Flex control 3.4. Approximately 2 µl of the 
prepared sample was spot onto a MTP 384 MALDI target plate and allowed to dry. The 
samples were ionized with a 337 nm laser and the spectra were acquired in a linear positive 
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mode at 17 kV using 500 laser shots per spectrum. A scan range of m/z = 0 – 35,000 Da 
was used. The spectra was internally calibrated using a protein mixture (Insulin [M+H]+ 
5,734.51 Da, Cytochrome C [M+H]+ 12,360.97 Da, Cytochrome C [M+2H]2+ 6,180.99 Da, 
Myoglobin [M+H]+ 16,952.30 Da, Trypsinogen [M+H]+ 23,982 Da) and the spectra were 
automatically processed using the FlexAnalysis Software (Bruker Daltonics) for data 
interpretation. 
3.5. Cell uptake experiments 
3.5.1. Cell culture 
3.5.1.1. Prostate cancer cell lines 
Three different prostate cell lines was used to assess the VNPs in vitro. The first cell line 
was a normal prostate cell line, PNT2. This cell line was derived from prostate epithelial cells 
and was immortalized by transfection with Simian virus 40 (Berthon et al., 1995). The second 
cell line, VCaP, is representative of an androgen dependent (early stage cancer) cell line. 
This cell line was derived from a metastatic site at the lumbar vertebrae in a prostate cancer 
patient (Korenchuk et al., 2001). The third cell line, PC3, represents late stage cancer in 
which the tumours have become androgen independent. This cell line was derived from a 
adenocarcinoma metastatic to bone tissue (Kaighn et al., 1979). 
 
Figure 3.1: Micrographs of the three different prostate cell lines, (A) PNT2, (B) VCaP, (C) PC3. Obtained from 
http://www.phe-culturecollections.org.uk/ and https://www.atcc.org. 
3.5.1.2. Culturing of cells 
PNT2, PC3 and VCaP cell lines were obtained from the Biochemistry Department at 
Stellenbosch University. PNT2 and PC3 cells were maintained in Advanced Roswell Park 
A B C 
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Memorial Institute (RPMI) 1640 reduced serum medium (Gibco®, Life Technologies), 
supplemented with 1 x GlutaMAX™ (Gibco®, Life Technologies), 1 % (v/v) Gentamicin 
(Gibco®, Life Technologies) and 6 % (v/v) fetal bovine serum (FBS) Superior (Biochrom 
GmbH). VCaP cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) + 
GlutaMAX™ (Life Technologies), supplemented with 1 % (v/v) Gentamicin and 10 % (v/v) 
FBS Superior. 
Cells were stored in a liquid nitrogen tank, in the appropriate medium supplemented with   
10 % (v/v) DMSO. Cells were thawed and added to a 25 cm2 flask with pre-warmed media 
and cultured at 37 °C in an ESCO CelCulture CO2 incubator within a humidified atmosphere 
and 5 % CO2. The medium was initially refreshed 24 hours after it was first seeded into a 
new flask. Thereafter the medium was refreshed after every 48 hours. 
Cells were subcultured by first removing old medium and washing the bottom of the flask 
with Dulbecco’s Phosphate Buffered Saline (DPBS), without CaCl2 and MgCl2, (Gibco®, Life 
Technologies). The cells were incubated with pre-warmed (0.25 %) Trypsin-EDTA (Life 
Technologies) for a maximum of 10 minutes at 37 °C. The flasks were visualized under the 
Olympus IX51 inverted light microscope to verify whether they have dissociated from the 
bottom of the flask. The trypsin was inactivated by adding twice the volume of medium and 
subjected to centrifugation at 1,500 rpm using a IEC Centra® CL2 centrifuge (IEC 236 rotor). 
The pellets were resuspended in 1 ml media and seeded at a 1:3 ratio into 75 cm2 flasks 
containing pre-warmed media. Cells were maintained at 80 % confluency. 
3.5.2. Flow cytometry 
The cells were removed from the flasks similarly to what was described previously, with the 
exception of cell dissociation buffer (Gibco®, Life Technologies) used as opposed to trypsin. 
The cells were incubated at 37 °C for a maximum of 30 minutes. The cell dissociation buffer 
is enzyme-free which keeps the receptors on the surface of the cells intact for uptake 
experiments. After centrifugation the pellets were again resuspended in 1 ml of the 
appropriate medium and cells were counted using in an Invitrogen™ Countess™ Automated 
Cell Counter. For the counting, 10 µl of the cells were added to 10 µl Trypan blue stain (0.4 
%) (Life Technologies) and 10 µl of the mixture was loaded onto a Countess™ cell counting 
chamber slide (Invitrogen) which was used in the cell counter. A total of 500,000 cells were 
seeded into a 96 well v-bottom plate and medium was added to a final volume of 200 µl 
where needed. 
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Cells were treated with particles in triplicate (three biological repeats, each with three 
technical repeats) and a negative control was left untreated, also with three biological 
repeats. The number of particles added per well was calculated using the following formula: 
𝑔 𝑉𝑁𝑃 𝑝𝑒𝑟 𝑐𝑒𝑙𝑙 =
100,000
6.022𝑥1023
× 4.6 × 106 = 7.638 × 10−13𝑔 𝐵𝑀𝑉 𝑝𝑒𝑟 𝑐𝑒𝑙𝑙 
Here, 100,000  refers to the number of VNPs added per cell. 6.022𝑥1023 is Avogadro’s 
constant which is equivalent to the number of molecules in one mole. The molecular weight 
of the VNP is given by 4.6 × 106. 
Each well has 500,000 cells, therefore 7.638 x 10-13 g of BMV per cell multiplied by 500,000 
equals 3.82 x 10-7 g BMV per well. This translates to 0.382 µg of BMV per well. A stock 
solution of 38 µg/ml was made up in order for 10 µl BMV to be added to each well for a total 
0.382 µg BMV per well. The plates were incubated with the particles for 2 hours at 37 °C, 
covered with foil. 
After incubation, the cells were subjected to centrifugation at 1500 x g for 5 minutes using 
the Eppendorf Centrifuge 5430 R (5430/R rotor). The pellets were resuspended in 200 µl 
FACS buffer (0.1 ml 0.5 M EDTA, 0.5 ml FBS, 1.25 ml 1 M HEPES pH 7, in a final volume 
of 50 ml in 1 x PBS). This step was repeated twice and the cells were then fixed in 200 µl of 
2 % (v/v) paraformaldehyde (in FACS buffer) for 10 minutes. The cells were again subjected 
to centrifugation and the wash steps in FACS buffer was repeated. The cells were stored in 
FACS buffer at 4 °C, for a maximum of 24 hours, until flow cytometry.  
The samples were analyzed using the BD FACSAria™ Cell Sorter (Becton Dickinson) at the 
Fluorescence Microscopy Unit of the CAF at Stellenbosch University. The analysis was 
performed by collecting a minimum of 20,000 cells at a flow rate of 2 using the 633 nm laser. 
Fluorescence intensity signal was measured using the geometric mean on the intensity 
histogram and data was obtained using the BD FACSDiVa v6.1.3 Software. The data was 
subsequently analyzed by using the FlowJo™ (FlowJo, 2016) and GraphPad Prism 
Software (GraphPad Prism, 2012). The percentage uptake of the VNPs was calculated by 
the BD FACSDiVa v6.1.3 Software from the number of positive events recorded. 
3.5.3. Fluorescence microscopy 
The cells were prepared and counted using the same protocol for flow cytometry (Section 
3.5.2, pages 32-33). A total of 500,000 cells were seeded onto coverslips in a 6 well flat 
bottom plate. Prior to adding the cells, the coverslips were sterilized by washing with 70 % 
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(v/v) ethanol three times and subsequently with PBS three times. The coverslips were 
covered by adding 1 ml of the appropriate medium into each well. The cells were allowed to 
adhere and grow on the coverslips overnight. 
Particles were added in triplicate (with three biological repeats), but in some cases only one 
biological sample was treated with the particles. One negative control was left untreated. 
The same formula was used to calculate the number of particles to add to each well, with a 
total of 0.382 µg BMV added per well. The cells were incubated with the particles for 4 hours 
at 37 °C, covered with foil.  
After the incubation, the cells were washed three times with PBS and then fixed at room 
temperature for 5 minutes with 1 ml of the fixative (2.94 ml PBS [1 x stock], 60 µl 2.5 % [v/v] 
glutaraldehyde, 2 ml paraformaldehyde [4 % (w/v) stock]). The cells were again washed 
three times with PBS and stained with DAPI (Sigma-Aldrich®) in a ratio of 1:500 (300 mM 
stock) in PBS for 15 minutes. The cells were washed with PBS three times for 5 minutes per 
wash step and subsequently stained with wheat germ agglutinin (WGA) Alexa Fluor® 488 
conjugate (Life Technologies) in a ratio of 1:500 (1 mg/ml stock) in PBS for 45 minutes. The 
cells were washed with PBS three times for 5 minutes per wash step. The cover slips were 
then mounted onto microscope slides with the aiding of Fluoroshield™ histology mounting 
medium (Sigma-Aldrich®) and the edges of the coverslips were sealed using clear nail 
polish. The slides were kept in the dark at 4 °C until visualization. 
The microscope images were obtained using the Carl Zeiss Laser Scanning Microscope 
(LSM780) ELYRA S.1 (Carl Zeiss) at the Fluorescence Microscopy Unit of the CAF at 
Stellenbosch University. Cells were imaged using the LCI Plan-Apochromat 63x/1.4 Oil DIC 
M27 objective and detected by means of a 633 nm, 488 nm and a diode 405 nm CW/PS 
laser. Images were processed using the Zen 2.1 (black) Software (Zeiss) (Zen 2.1 (black), 
2015). 
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Chapter 4 
Results and discussion 
4.1. Diagnostics 
4.1.1. RT-PCR 
In order to amplify the coat proteins, RT-PCR was performed. The infected N. benthamiana 
(Figure 4.1, panel A, lane 2) received from DAFF and the N. benthamiana inoculated with 
the virus (Figure 4.1, panel A, lane 3) were screened. The one-step RT-PCR did not amplify 
the expected amplicon (Figure 4.1, panel A). We therefore extracted RNA and rather did a 
two-step reaction; an initial cDNA synthesis followed by the PCR. Good quality RNA was 
extracted and BMV was positively diagnosed with the RT-PCR (Figure 4.1, panel B). The 
band corresponds to the expected amplicon size of 521 bp. This result indicates that the 
primers successfully amplified the coat protein of BMV. The inoculated N. benthamiana was 
also positively diagnosed after sufficient propagation. 
 
Figure 4.1: RT-PCR of BMV infected source material. (A) 1.5 % TAE-agarose gel with ethidium bromide 
staining, of one-step RT-PCR amplicons generated using BMV primers. Lane 1: O’GeneRuler™ 100 bp Plus 
DNA Ladder (Thermo-Scientific), Lane 2: Infected N. benthamiana, Lane 3: Inoculated N. benthamiana. (B) 
1.5 % TAE-agarose gel with ethidium bromide staining, of two-step RT-PCR amplicons generated using BMV 
primers. Lane 1: GeneRuler™ 1 kb ladder (Thermo-Scientific), Lane 2: Amplicon. 
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4.1.2. Dot-blot 
An immuno dot-blot was performed in order to diagnose BMV in the infected leaf material. 
BMV was positively diagnosed by means of the immuno dot-blot. This is presented as dark 
spots in Figure 4.2. Purified BMV samples were obtained from the Biopharming Research 
Unit (BRU) at the University of Cape Town (UCT) and were used as a positive control (Figure 
4.2, 2). The negative control (Figure 4.2, 1) represents uninfected N. benthamiana leaves 
that were ground in sodium acetate buffer and blotted on the membrane to test for any 
nonspecific binding of the antibody. From Figure 4.2 we observe that a faint spot is present 
at the negative control, however, the BMV samples are much darker which indicates true 
binding of the antibody. From this analyses we conclude that we successfully infected N. 
benthamiana with BMV. 
 
Figure 4.2: Dot-blot of purified BMV. 1) Negative control, 2) BMV positive control, 3) Purified BMV 
4.2. Virus Purification 
4.2.1. Inoculation and propagation 
BMV was propagated in N. benthamiana in order to increase the virus concentration. 
Characteristic mosaic and chlorotic symptoms appeared in N. benthamiana after 
propagating for two weeks (Figure 4.3), which is consistent with literature (Lane, 1974) . The 
leaves were harvested after three weeks to ensure high virus titer in the infected plants. 
1                                2                                3 
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Figure 4.3: N. benthamiana infected with BMV. Characteristic symptoms are visible. 
4.2.2. Purification 
BMV was purified from the leaf material in order to produce pure particles for bioconjugation 
experiments. The purification of BMV using method 1 was unsuccessful (Figure 4.4, panel 
A). The virus particles were present in the aqueous phase during the chloroform step and 
not in the pellet as indicated by the protocol. The second purification method, which utilized 
a longer PEG precipitation incubation time and omitted a chloroform step, could successfully 
purify BMV from the infected leaf material. The purified particles could be visualized on the 
TEM as is shown on Figure 4.4, panel B. Their average diameter was found to be 28 nm, 
as expected. 
 
Figure 4.4: Electron micrograph of purified BMV. (A) BMV purified using method 1, no particles are present. 
(B) BMV purified using method 2. The average diameter of the particles is 28 nm. 
A B 
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Table 4.1 indicates the protein concentrations and absorbance ratios of 260/280 for both 
methods. The protein concentration indicates that method 2 is more efficient for purifying 
BMV, since the yield is twice as high. The absorbance ratio of 260/280 is used to assess 
the purity and integrity of the virus (Yildiz et al., 2012) and this also indicates a successful 
purification. For BMV a 260/280 absorbance ratio of 1.7 indicates pure and intact virus 
particles (Bockstahler and Kaesberg, 1962; Yildiz et al., 2012). The electron micrograph also 
confirmed that the particles were intact (Figure 4.4, B). This was therefore the preferred 
method for purification of BMV from N. benthamiana for the remainder of the study. The 
purifications yielded an average of 800 mg purified particles per kilogram of leaf material 
and had a 260/280 ratio of 1.73 (Table 4.1, Sample: Purified BMV). 
Table 4.1: Spectrophotometer results for purified BMV produced using two different 
purification methods 
Sample Protein concentration (mg/ml) 260/280 
BMV from method 1 (aqueous layer) 3.597 1.55 
BMV from method 2 10.274 1.74 
Purified BMV 80.155 1.73 
4.3. Bioconjugation 
BMV was labeled with a fluorescent molecule in order to facilitate the movement of the VNPs 
in vitro. It was also conjugated with a targeting peptide with the aim of increasing the 
internalization into the cells. Initially two different buffers were used in the EDC reaction, 
namely a sodium acetate buffer and a HEPES buffer. Since BMV is usually not stable at a 
pH higher than 6 (Pfeiffer and Hirth, 1975), we decided that the low pH sodium acetate buffer 
may be more suitable for the virus. The preparation from the fluorescent labeling did not 
indicate a significant difference in yield or integrity for the two different buffers (Table 4.2). 
However, a total of 8 fluorescent molecules were found to be bound for the HEPES buffer, 
whereas for the sodium acetate buffer no molecules were bound. The STEM analysis3 
indicated that the sodium acetate buffer produced particles that were not intact, while the 
particles from the HEPES buffer were all intact. These results suggest that the HEPES 
                                                            
3 These images will not be presented here due to low resolution of the images produced. The STEM analysis was 
performed to validate the integrity of the particles before proceeding with subsequent steps. 
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buffer, with a pH of 7.4, is necessary to facilitate the reaction as suggested by the protocol 
from Bruckman and Steinmetz (2014). 
Table 4.2: Virus concentration, based on the absorbance at 260 nm, for EDC and CuAAC 
reaction utilizing both sodium acetate and HEPES buffer 
Sample 
Concentration 
(mg/ml) 
260/280 
Fluorescent 
molecules 
bound 
BMV-Alkyne (sodium acetate buffer) 0.83 1.42 N/A* 
BMV-Alkyne (HEPES buffer) 1.18 1.38 N/A* 
BMV-AlexaFluor 647 (sodium acetate buffer) 0.62 1.73 <1 
BMV-AlexaFluor 647 (HEPES buffer) 0.71 1.68 8 
*N/A – not applicable to this sample 
We proceeded with an upscale reaction as a larger volume of the preparation was needed 
for subsequent conjugations. However, a larger reaction volume (10 ml) resulted in 
precipitation and the absorbance ratio was lower when compared to the 1 ml reaction 
volume (Table 4.3). The 1 ml reaction volume produced a higher yield, and more intact 
particles were obtained. For this reason, we proceeded with 1 ml reaction volumes, which 
were combined during the ultracentrifugation step. 
Table 4.3: Spectrophotometer results for the concentration, purity and fluorescent labeling 
efficiency of BMV-Alkyne and BMV-AlexaFluor 647 using either a 10 ml, or multiple 1 ml 
reactions.  
Sample Concentration (mg/ml) 260/280 
Fluorescent molecules 
bound 
BMV-Alkyne (10 ml) 53.979 1.03 N/A* 
BMV-Alkyne (1 ml) 61.413 1.2 N/A* 
BMV-AlexaFluor 647 (1 ml) 0.16 1.39 120 
*N/A – not applicable to this sample 
The results for the CuAAC reaction using the BMV-Alkyne from the separate 1 ml reactions 
were favorable (Table 4.3). This sample was used for an initial passive uptake experiment 
in the different cell lines (Figures 4.17 and 4.18). We proceeded with another EDC and 
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CuAAC reaction, and the resulting preparation was used in a peptide conjugation 
experiment. The spectrophotometer results for these preparations were favorable (Table 
4.4). The first peptide conjugation produced intact particles as indicated by the STEM 
visualization. 
Table 4.4: Virus concentrations, purity and fluorescent labeling efficiency, based on the 
absorbance at 260 nm, of BMV-Alkyne, BMV-AlexaFluor 647 and peptide conjugated BMV 
Sample Concentration (mg/ml) 260/280 
Fluorescent molecules 
bound 
BMV-Alkyne 68 1.46 N/A* 
BMV-AlexaFluor 647 34.66 1.68 35 
BMV-SM(PEG)8-P1 0.22 1.63 35 
BMV-SM(PEG)12-P1 0.34 1.71 35 
BMV-SM(PEG)24-P1 0.25 1.61 35 
*N/A – not applicable to this sample 
The SDS-PAGE gel (Figure 4.5) shows the separation of the different samples. An amount 
of 10 µg per sample was loaded onto the gel. We expected to see two bands, which indicate 
that the reaction was successful. The bottom band corresponds to the coat protein of BMV 
(Figure 4.5, panel A, lane 2 and panel B, lane 5), which is 20 kDa in size. The top band 
represents the BMV-peptide conjugate, which shows a size increase and therefore migrates 
slower on the gel. The bands are very light as only 10 µg could be loaded onto the gel.  
The coat protein band for BMV is lower than the expected 20 kDa size. It has previously 
been demonstrated that the native T=3 conformation of BMV is able to transform into a T=1 
conformation at pH higher than 7, and a high salt concentration. This T=1 BMV has a 
molecular weight of approximately 16,450 Da, as confirmed by SDS-PAGE and mass 
spectrometry (Larson et al., 2005; Lucas et al., 2001). This could indicate that the native 
BMV particles transform into T=1 particles in the presence of the sample buffer. 
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Figure 4.5: SDS-PAGE gel of BMV-AlexaFluor® 647 conjugated with Peptide 1 and three different 
crosslinkers, run at 120 V. (A) Lane 1: BMV-SM(PEG)8-P1, conjugate indicated by the red block, Lane 2: 
Unmodified BMV, Lane 3: Precision Plus Protein™ Standard Ladder. (B) Lane 1: BMV-SM(PEG)24-P1, 
conjugate indicated by the arrow and red block, Lane 2: BMV-SM(PEG)24, Lane 3: BMV-SM(PEG)12-P1, Lane 
4: BMV-SM(PEG)12, Lane 5: Unmodified BMV, Lane 6: Precision Plus Protein™ Standard Ladder 
In panel B, lanes 2 and 4 correspond to only the BMV-crosslinker conjugate, before the 
peptide was added to the reaction.4 Only the BMV-SM(PEG)24-P1 reaction (panel B, lane 1) 
indicated a second band, as indicated by the red block and arrow. This shows that the 
peptide is bound to the coat protein. These samples were used for an initial active uptake 
experiment in all three cell lines (Figures 4.19 and 4.20).  
Due to a limited volume of the preparation that was available, repeated upscale reactions 
were required. However, in the 1 ml EDC reaction, a precipitation was observed. This was 
unexpected as it previously only occurred when a reaction volume greater than 1 ml was 
used. We first performed a 1 ml CuAAC reaction to validate whether the precipitation 
affected the fluorescent labeling, and then proceeded with the upscale reaction. The results 
were favorable, except for the low absorbance ratio and lower yield of the upscale reaction 
(Table 4.5).  
                                                            
4 During the reaction 10 µl of the reaction was stored before the peptide was added to the reaction, but this was too 
little to visualize on the gel. 
A B 
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We investigated whether the purified stock of BMV led to the precipitation and therefore 
included two purified BMV stocks obtained from UCT (BMV 1 and BMV 2). The results   
(Table 4.5) indicated that our own purified BMV had comparable fluorescent binding and 
therefore we conclude that this is not the cause of the precipitation.  
Table 4.5: Virus concentrations, based on the absorbance at 260 nm, of BMV-Alkyne and 
BMV-Cy5 for various optimization steps 
Sample 
Concentration 
(mg/ml) 
260/280 
Fluorescent molecules 
bound 
BMV-Alkyne 94.3 1.28 N/A* 
BMV-Cy5 (1 ml) 3.322 1.68 60 
BMV-Cy5 (upscale) 3.761 0.89 28 
BMV-Alkyne (our sample) 18.252 1.23 N/A* 
BMV-Alkyne (BMV 1) 14.425 1.07 N/A* 
BMV-Alkyne (BMV 2) 19.423 1.22 N/A* 
BMV-Cy5 (our sample) 0.594 1.62 41 
BMV-Cy5 (BMV 1) 0.478 1.56 47 
BMV-Cy5 (BMV 2) 0.433 1.59 49 
*N/A – not applicable to this sample 
We performed another scaled-up reaction with good yield and a total of 32 fluorescent 
molecules bound. The particles were visualized on a TEM to ensure that they were intact 
before proceeding with subsequent reactions.5 The particles produced from the EDC   
(Figure 4.6, panel A) and CuAAC reactions (Figure 4.6, panel B) were intact. 
The peptide conjugations from this preparation were successful with regards to yield and 
absorbance ratio (Table 4.6). The particles were all intact (Figure 4.6, panels C-F and panel 
H), with the exception of BMV-SM(PEG)12-P2 (Figure 4.6, panel G). The SDS-PAGE gel 
indicated a second band for BMV-SM(PEG)24-P1 (Figure 4.7, lane 5) and BMV-SM(PEG)24-
P2 (Figure 4.7, lane 8), as shown by the red blocks and red arrows. This indicates that the 
                                                            
5 The TEM does not have a high enough resolution power to indicate the modifications on the surface of the virus coat 
protein and therefore the images are only an indication of the integrity of the particles. 
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peptide is bound to BMV. These samples were used in uptake experiments in the all the cell 
lines (Figures 4.21, 4.22 and 4.27). 
 
Figure 4.6: Electron micrograph of (A) BMV modified using the EDC reaction, (B) BMV conjugated with the 
Cy5 fluorescent molecule, (C) BMV-Cy5 conjugated with SM(PEG)8 and Peptide 1, (D) BMV-Cy5 conjugated 
with SM(PEG)12 and Peptide 1, (E) BMV-Cy5 conjugated with SM(PEG)24 and Peptide 1, (F) BMV-Cy5 
conjugated with SM(PEG)8 and Peptide 2, (G) BMV-Cy5 conjugated with SM(PEG)12 and Peptide 2, the red 
arrow indicates particles that are not intact, (H) BMV-Cy5 conjugated with SM(PEG)24 and Peptide 2 
 
 
A B C 
D E F 
G H 
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Table 4.6: Virus concentrations, based on the absorbance at 260 nm, for BMV modified with 
the Peptide 1 and 2 using two different BMV-Cy5 samples 
Sample Concentration (mg/ml) 260/280 
BMV-SM(PEG)8-P1 0.831 1.66 
BMV-SM(PEG)12-P1 0.810 1.7 
BMV-SM(PEG)24-P1 0.326 1.65 
BMV-SM(PEG)8-P2 0.965 1.56 
BMV-SM(PEG)12-P2 1.254 1.66 
BMV-SM(PEG)24-P2 1.468 1.63 
 
 
Figure 4.7: SDS-PAGE gel of BMV-Cy5 conjugated with Peptide 1 and 2 and three different crosslinkers, run 
at 120 V. Lane 1: Precision Plus Protein™ Standard Ladder, Lane 2: Unmodified BMV, Lane 3: BMV-
SM(PEG)8-P1, Lane 4: BMV-SM(PEG)12-P1, Lane 5: BMV-SM(PEG)24-P1, conjugate indicated by the arrow, 
Lane 6: BMV-SM(PEG)8-P2, Lane 7: BMV-SM(PEG)12-P2, Lane 8: BMV-SM(PEG)24-P2, conjugate indicated 
by the arrow 
The samples were also analyzed using MALDI-TOF MS. The two peptides were found to be 
intact with their expected sizes of 950.08 Da and 846.96 Da, while the size of BMV was 
determined to be 20,284 Da, as expected. In Figure 4.8, an approximate size of 20,380 Da 
can be observed for BMV-Cy5, as indicated by the largest peak. A second peak is observed 
20 kDa 
17 kDa 
 
1              2              3              4              5              6              7              8 
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for BMV-SM(PEG)12-P1 (Figure 4.8, panel B), BMV-SM(PEG)24-P1 (Figure 4.8, panel C), 
BMV-SM(PEG)8-P2 (Figure 4.8, panel D) and BMV-SM(PEG)12-P2 (Figure 4.8, panel E).  
 
Figure 4.8: MALDI-TOF MS analysis of BMV-Cy5 conjugated with (A) SM(PEG)8-P1, (B) SM(PEG)12-P1, (C) 
SM(PEG)24-P1, (D) SM(PEG)8-P2, (E) SM(PEG)12-P2, (F) SM(PEG)24-P2 
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This is contradictory to the result from SDS-PAGE (Figure 4.7), which showed that only 
conjugates BMV-SM(PEG)24-P1 and BMV-SM(PEG)24-P2 was successfully conjugated with 
the peptides. 
We confirmed the successful conjugation of BMV with Peptide 1 and Peptide 2 by using the 
crosslinker SM(PEG)24 (Figure 4.9). Unmodified BMV was used and the presence of the 
peptide conjugate is indicated by the second band. 
 
Figure 4.9: SDS-PAGE gel of native BMV conjugated with Peptide 1 and 2 and crosslinker SM(PEG)24, run at 
120 V. Lane 1: Precision Plus Protein™ Standard Ladder, Lane 2: Unmodified BMV, Lane 3: BMV-SM(PEG)24-
P1, Lane 4: BMV-SM(PEG)24-P2 
In a following EDC reaction, no precipitation was observed for the 1 ml reaction volume.6 
The particles for the EDC modification (Figure 4.10, panel A) and fluorescent labeling 
(Figure 4.10, panel B) were intact. An excellent yield was obtained and 50 fluorescent 
molecules were bound. The spectrophotometry results (Table 4.7) for the peptide 
conjugation indicate excellent yield and that intact particles were produced. TEM images 
were obtained for BMV-SM(PEG)24-P1 (Figure 4.10, panel C) and BMV-SM(PEG)24-P2        
(Figure 4.10, panel D). 
 
 
 
 
                                                            
6 The previously observed precipitation was found to be due to crystals forming in the propargylamine. For the 
subsequent reactions a new tube was used. 
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Table 4.7: Virus concentrations, based on the absorbance at 260 nm, for BMV-Cy5 modified 
with Peptide 1 and 2 and crosslinkers SM(PEG)8, SM(PEG)12 and SM(PEG)24 
Sample Concentration (mg/ml) 260/280 
BMV-SM(PEG)8-P1 2.998 1.64 
BMV-SM(PEG)12-P1 1.581 1.64 
BMV-SM(PEG)24-P1 3.522 1.60 
BMV-SM(PEG)8-P2 1.342 1.62 
BMV-SM(PEG)12-P2 2.732 1.64 
BMV-SM(PEG)24-P2 1.592 1.63 
 
 
 Figure 4.10: Electron micrograph of (A) BMV modified using the EDC reaction, (B) BMV conjugated with the 
Cy5 fluorescent molecule, (C) BMV-Cy5 conjugated with SM(PEG)24 and Peptide 1, (D) BMV-Cy5 conjugated 
with SM(PEG)24 and Peptide 2 
A B 
C D 
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There was no second conjugate band present on the SDS-PAGE gel (Figure 4.11). The 
previous peptide conjugation to the native BMV was used as a control (Figure 4.11, lane 9 
and 10) as this was previously confirmed on the gel. This indicates that the peptide is not 
bound. These samples were still used in the cell uptake experiments (Figures 4.23, 4.24 
and 4.28). 
 
Figure 4.11: SDS-PAGE gel of BMV-Cy5 conjugated with Peptide 1 and 2 and crosslinkers SM(PEG)8, 
SM(PEG)12 and SM(PEG)24, run at 120 V. Lane 1: Precision Plus Protein™ Standard Ladder, Lane 2: 
Unmodified BMV, Lane 3: BMV-SM(PEG)8-P1-Cy5, Lane 4: BMV-SM(PEG)12-P1-Cy5, Lane 5: BMV-
SM(PEG)24-P1-Cy5, Lane 6: BMV-SM(PEG)8-P2-Cy5, Lane 7: BMV-SM(PEG)12-P2-Cy5, Lane 8: BMV-
SM(PEG)24-P2-Cy5, Land 9: BMV positive control BMV-SM(PEG)24-P1, Lane 10: BMV positive control BMV-
SM(PEG)24-P1 (lower concentration) 
We validated the conjugation of the different crosslinkers with both peptides, by conjugating 
them to unmodified BMV. The SDS-PAGE gel confirmed that only crosslinker SM(PEG)24 
successfully conjugated both Peptide 1 and 2 to the BMV coat protein (Figure 4.12, lanes 4 
and 7). These results are contradictory to those received from the MALDI-TOF MS analysis, 
nevertheless we decided to proceed with only crosslinker SM(PEG)24 for the remainder of 
the study. This successful conjugation is contradictory to the previous results (Figure 4.11) 
where none of the crosslinkers bound the peptide to BMV.  
We suspected that the fluorescent labeling may inhibit the subsequent peptide conjugation. 
This was investigated by first conjugating the peptide to the virus and then proceeding with 
the fluorescent labelling. We confirmed that the peptide was bound to the virus after the 
initial peptide conjugation   (Figure 4.13, panel A) and after the fluorescent labeling (Figure 
4.13, panel B, lane 3). Good yield and mostly intact particles were obtained. We calculated 
a total of 51 fluorescent molecules bound, which indicated that conjugation of the peptide 
before the fluorescent molecule does not impact the efficiency of fluorescent labeling.  
CP + Peptide 
CP 
 
20 kDa 
17 kDa 
 
1           2         3          4          5           6           7          8         9          10 
Stellenbosch University  https://scholar.sun.ac.za
50 
 
 
Figure 4.12: SDS-PAGE gel of native BMV conjugated with Peptide 1 and 2 and crosslinkers SM(PEG)8, 
SM(PEG)12 and SM(PEG)24, run at 120 V. Lane 1: Precision Plus Protein™ Standard Ladder, Lane 2: BMV-
SM(PEG)8-P1, Lane 3: BMV-SM(PEG)12-P1, Lane 4: BMV-SM(PEG)24-P1, conjugate indicated in red block, 
Lane 5: BMV-SM(PEG)8-P2, Lane 6: BMV-SM(PEG)12-P2, Lane 7: BMV-SM(PEG)24-P2, conjugate indicated 
in red block, Lane 8: Unmodified BMV 
We also attempted to first incubate the peptide and the linker together and then conjugate it 
to the fluorescently labeled virus. This was to investigate whether the problem lies with the 
linker binding to the virus or the peptide binding to the linker after the fluorescent labeling.  
 
Figure 4.13: SDS-PAGE gel of BMV conjugated with Peptide 1 and SM(PEG)24, run at 120 V. (A) Lane 1: 
Unmodified BMV, Lane 2: BMV-SM(PEG)24-P1 of native BMV, Lane 3: Precision Plus Protein™ Standard 
Ladder. (B) Lane 1: Precision Plus Protein™ Standard Ladder, Lane 2: Unmodified BMV, Lane 3: BMV-
SM(PEG)24-P1-Cy5 (reverse), Lane 4: BMV-SM(PEG)24-P1-Cy5 (peptide-linker incubated) 
The fluorescent labeling achieved 52 molecules bound and all the particles were intact. The 
peptide was however not bound (Figure 13, panel B, lane 4), as only a single band of             
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17 kDa was present. This provided further evidence that the fluorescent labeling might 
impede peptide conjugations. 
4.3.1. Alternative conjugation method 
We investigated the structure of the coat protein to verify whether the glutamic acids and 
lysines could cause steric hindrance during conjugation. We generated an image of the coat 
protein structure (Figure 4.14) using Chimera (v.1.11.2) (Pettersen et al., 2004). The red 
arrow indicates a representative section of the interaction between the glutamic acid and 
the lysine residues. Here we observe that a large proportion of the two amino acids appear 
in the same location. This might explain why the peptide conjugation is less efficient when 
the fluorescent labeling is performed first. The fluorescent molecule, bound to the glutamic 
acid, could cause steric hindrance which prevents the peptides from conjugating. This may 
not be the case for every lysine residue, but could affect enough of them for too few of the 
conjugates to be separated on the SDS-PAGE gel, thereby explaining the lack of a double 
band. This might also explain why the gel was negative for the peptide conjugation, but was 
positively confirmed with the MALDI-TOF MS. Due to this interference and the reverse 
reaction not being efficient, we proceeded with a different approach. 
 
Figure 4.14: Section of the exterior coat protein of BMV indicating the glutamic acid and lysine residues. The 
arrow indicates where the glutamic acid and lysine co-occur. The glutamic acids are highlighted in the yellow 
circles and the lysines in the pink circles. 
We conjugated both the fluorescent molecule and the peptide to the lysine residues. 
Fluorescent binding for Peptide 1 and 2 was 40 and 60 molecules respectively. TEM 
analysis showed that the particles produced in the Peptide 2 reaction (Figure 4.15, panel B) 
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were completely intact, but the particles from the Peptide 1 reaction (Figure 4.15, panel A) 
were not all intact with only a few aggregated particles present.  
 
Figure 4.15: Electron micrograph of BMV-Cy5 conjugated with a crosslinker and two peptides. (A) SM(PEG)24 
and Peptide 1, particles are not intact. (B) SM(PEG)24 and Peptide 2, particles are intact. 
 
 
Figure 4.16: SDS-PAGE gel of BMV conjugated with Peptide 1 and 2 and SM(PEG)24 using an alternative 
method, run at 120 V. Lane 1: Precision Plus Protein™ Standard Ladder, Lane 2: Unmodified BMV, Lane 3: 
BMV-SM(PEG)24-P1, Lane 4: BMV-SM(PEG)24-P2 
The peptide binding was successful as indicated by double bands for both reactions     
(Figure 4.16). This indicates that this conjugation method not only produced intact particles, 
at least for Peptide 2, but also excellent fluorescent labeling and peptide conjugation. This 
is therefore the conjugation method of choice for BMV. These samples were used in uptake 
experiments in all cell lines (Figures 4.25, 4.26 and 4.29). 
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4.4. Cell uptake experiments 
4.4.1. Flow cytometry 
The internalization of the VNPs were assessed in three different prostate cell lines by means 
of flow cytometry. Previous studies on BMV (Daniel et al., 2010; Dixit et al., 2006; Huang et 
al., 2011, 2007; Sun et al., 2007; Yildiz et al., 2012) have not accessed the uptake of the 
VNPs into cell lines even though the encapsulation and bioconjugation was successful. Jung 
et al., (2011) demonstrated that BMV encapsulated with a fluorescent molecule is 
internalized into human bronchial epithelial cells. It is therefore unclear with what percentage 
BMV will be taken up into the prostate cells.  
The initial flow cytometry experiments for the passive uptake of BMV into the three cell lines 
(Figure 4.17) indicated significant uptake in only the PNT2 cell line. This is also 
demonstrated by the mean fluorescence intensity in the cells (Figure 4.18). The uptake is 
quite high for PNT2, which is expected since this is only passive uptake and we would expect 
the normal cell line to allow more molecules to enter, whereas the physiological 
characteristics of the cancer cells may prevent this. 
The first active uptake results (Figure 4.19) indicate that the presence of a targeting ligand 
improves the efficiency of the internalization of the VNPs. The ligand facilitates the 
internalization of the VNPs by means of receptor-mediated endocytosis. This form of 
endocytosis makes use of a selective internalization in which only molecules with the 
complementary ligand to the receptor on the cell will be internalized. When the ligand binds 
to the receptor on the cell surface, the membrane will form a vesicle around the molecule 
and release it in the interior of the cell (Cooper, 2000). Previous studies on CPMV as a VNP 
indicated that when conjugated with a bombesin ligand, targeting the GRP receptor, the 
internalization was increased (Steinmetz et al., 2011). We would therefore expect that the 
VNPs with the targeting ligand will be internalized with a higher percentage. 
We also observed that the passive uptake was not significant. The VCaP cell line had the 
highest uptake, while PNT2 and PC3 had similar uptake. We observe a significant increase 
in uptake for SM(PEG)12 and SM(PEG)24 compared to SM(PEG)8 (p<0.0001) for VCaP. For 
PC3 and PNT2 there is no significant difference in uptake among the different linkers. The 
mean fluorescent intensity (Figure 4.20) differs slightly from the percentage uptake in the 
Stellenbosch University  https://scholar.sun.ac.za
54 
 
cell lines.7 The higher uptake of VCaP compared to PC3 is unexpected, since the peptides 
are designed specifically for the receptors on androgen-independent cell lines. 
 
Figure 4.17: Percentage passive uptake of BMV-AlexaFluor® 647 in three different prostate cells, PNT2, VCaP 
and PC3. Significance was calculated using a two-way ANOVA with Bonferroni correction. Significance is 
indicated between treated and untreated cells: **** = p<0.0001. 
 
Figure 4.18: Mean fluorescence intensity indicating passive uptake into (A) PNT2, (B) VCaP and (C) PC3. 
Grey = Untreated cells, Blue = BMV-AlexaFluor 647 
                                                            
7 This could be caused by fewer cells containing VNPs, but each cell which does contain VNPs, has a large number of 
them. 
A B C 
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Figure 4.19: Percentage passive and active uptake of BMV-AlexaFluor® 647, conjugated to Peptide 1 and 
three different crosslinkers, in three different prostate cells, PNT2, VCaP and PC3. Significance was calculated 
using a two-way ANOVA with Bonferroni correction. Significance is indicated between treated and untreated 
cells: **** = p<0.0001 
 
Figure 4.20: Mean fluorescence intensity indicating passive and active uptake into (A) PNT2, (B) VCaP and 
(C) PC3. Grey = Untreated cells, Light blue = BMV- SM(PEG)8-P1, Medium blue = BMV- SM(PEG)12-P1, Dark 
blue = BMV- SM(PEG)12-P1 
In Figure 4.21 we present the first uptake data with three and more biological and technical 
repeats. In this case we observed that VCaP did not have any significant uptake, for both 
the passive and active uptake. Both PNT2 and PC3 had significant uptake, with the 
exception of BMV-SM(PEG)8-P1 in PNT2. Even though the uptake for PNT2 was still high, 
PC3 had significantly more uptake of the VNPs (p<0.0001). This suggests that the VNPs 
will tend to target the PC3 cells, which is the expected outcome. BMV-SM(PEG)24-P1 had 
the highest uptake and was significant compared to the passive (p<0.005) in PC3. This 
A B C 
Stellenbosch University  https://scholar.sun.ac.za
56 
 
sample also had a high fluorescent intensity (Figure 4.22, C), suggesting that a large number 
of VNPs enter the cells. The high passive uptake may be attributed to the normal 
endocytosis of molecules into the cells, but the targeting ligand present on the VNPs utilizes 
a receptor-mediated endocytosis which is more efficient and therefore a higher uptake is 
observed. 
The results correspond to the double band that was observed on the SDS-PAGE gel and 
was confirmed with MALDI-TOF MS analysis, and suggests that the peptide is bound to 
BMV and contributes to an increased internalization into the cancer cells. The results for 
BMV-SM(PEG)12-P1 are contradictory, since the MALDI-TOF MS analysis suggested that 
the peptide is bound, whereas the gel indicated that it is not bound. Further investigation 
confirmed that crosslinker SM(PEG)12 does not bind the peptide to BMV. This is also the 
case for crosslinker SM(PEG)8. 
 
Figure 4.21: Percentage passive and active uptake of BMV-Cy5, conjugated to Peptide 1 and three different 
crosslinkers, in three different prostate cells, PNT2, VCaP and PC3. Significance was calculated using a two-
way ANOVA with Bonferroni correction. Significance is indicated between treated and untreated cells: ns = 
p>0.05, **** = p<0.0001 
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Figure 4.22: Mean fluorescence intensity indicating passive and active uptake into (A) PNT2, (B) VCaP and 
(C) PC3. Light grey = Untreated cells, Dark grey = BMV-Cy5, Light blue = BMV- SM(PEG)8-P1, Medium blue 
= BMV- SM(PEG)12-P1, Dark blue = BMV- SM(PEG)12-P1 
For the final samples that utilized the conjugation of the fluorescent molecule to the glutamic 
acids and the peptide to the lysines, we did not observe significant uptake (Figure 4.23). 
This result was expected since we did not confirm any peptide bound on the gel. The passive 
uptake is significantly lower than expected. From the mean fluorescent intensity (Figure 
4.24) we also did not see high fluorescence, which suggests that the VNPs were not 
internalized.  
 
Figure 4.23: Percentage passive and active uptake of BMV-Cy5, conjugated to Peptide 1 and 2 and 
crosslinker SM(PEG)24, in two different prostate cells, PNT2 and PC3. Significance was calculated using a 
two-way ANOVA with Bonferroni correction. Non-significant uptake was observed. 
A B C 
Stellenbosch University  https://scholar.sun.ac.za
58 
 
 
Figure 4.24: Mean fluorescence intensity indicating passive and active uptake into (A) PNT2, (B) PC3. Dark 
grey = Untreated cells, Light grey = BMV-Cy5, Light blue = BMV- SM(PEG)24-P1, Dark blue = BMV- 
SM(PEG)24-P2 
The percentage uptake and mean fluorescent intensity for the VNPs produced by 
conjugating to only the lysines are presented in Figures 4.25 and 4.26. BMV-SM(PEG)24-P2 
had the highest uptake for all the cell lines. For the passive uptake we used the same sample 
that was reported in Figure 4.23, but in this case we have significant uptake. The result for 
PC3 was expected as the peptides are specific to the receptors on androgen-independent 
cancer cells. This could also explain why the uptake for Peptide 1 was much higher in PC3 
than for the other two cell lines. Even though PNT2 still had very high uptake, the uptake for 
PC3 was significantly higher (p<0.0001) for both Peptide 1 and 2 as calculated by the two-
way ANOVA. The high uptake for the PC3 cell line is consistent with findings in literature 
(Mandelin et al., 2015) where both peptides were targeted to the PC3 cells and not the 
control sarcoma cells that were used. They have identified that the receptors for the peptides 
are present on prostatic cell lines, but they have not investigated the presence on normal 
prostate cells. Therefore the PNT2 cell lines may also present with the respective receptors 
which would explain the high uptake. The significantly higher uptake in the PC3 cell lines 
would however suggest that the VNPs would rather internalize into the cancer cells than into 
the normal prostate cells. 
A B  B 
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Figure 4.25: Percentage passive and active uptake of VNPs produced by the conjugation to the lysines. BMV-
Cy5 conjugated to Peptide 1 and 2 and crosslinker SM(PEG)24 uptake in three different prostate cells, PNT2, 
VCaP and PC3. Significance was calculated using a two-way ANOVA with Bonferroni correction. Significance 
is indicated between treated and untreated cells: * = p<0.05, ** = p<0.005, **** = p<0.0001. 
 
Figure 4.26: Mean fluorescence intensity indicating passive and active uptake into (A) PNT2, (B) VCaP and 
(C) PC3. Dark grey = Untreated cells, Light grey = BMV-Cy5, Light blue = BMV- SM(PEG)24-P1, Dark blue = 
BMV- SM(PEG)24-P2 
4.4.2. Fluorescence microscopy 
The internalization of the VNPs were also assessed in the three prostate cell lines by means 
of florescence microscopy. The image acquisitions included a z-stack in order to assess the 
localization of the VNPs in the cells. The uptake for the different VNPs in PC3 is shown in 
Figure 4.27. We observed that the passive and active uptake for BMV-SM(PEG)8-P1 and 
BMV-SM(PEG)12-P1 corresponded with the findings from the flow cytometry. However, for 
A B C 
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BMV-SM(PEG)24-P1 the uptake was significantly lower. This could be explained by the fact 
that only a single focal plane was acquired. 
The results for the uptake of BMV-P1 and BMV-P2 (Figure 4.28) contradicted the non-
significant results we obtained from flow cytometry. In this case, the uptake of the virus in 
the cells was comparable to the uptake in Figure 4.27, which had significant flow cytometry 
results. This could be due to the difference in incubation time for flow cytometry and 
fluorescence microscopy. We can also see that the passive uptake (Figure 4.28, A and B) 
corresponds to the percentage uptake observed in Figure 4.25. 
In Figure 4.29 the uptake corresponds perfectly with the flow cytometry results and we 
observed high uptake of BMV-SM(PEG)24-P2 in all three cell lines and BMV-SM(PEG)24-P1 
in PC3. We performed a z-stack of the cells and confirmed that the particles were 
internalized. This confirms the positive result that we obtained earlier. 
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Figure 4.27: Micrograph of passive and active uptake of BMV-Cy5 conjugated with Peptide 1 and three 
different crosslinkers, uptake into PC3 cells. (A) BMV-Cy5, (B) BMV-SM(PEG)8-P1, (C) BMV-SM(PEG)12-P1, 
(D) BMV-SM(PEG)24-P1. The nucleus is stained in blue (DAPI) and the cell membrane in green (WGA). The 
VNPs are in red and can be located with the white arrows. The scale bar represents 10 µm. 
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Figure 4.28: Micrograph of passive and active uptake of BMV-Cy5 conjugated with Peptide 1 and 2 and 
crosslinker SM(PEG)24, uptake into PNT2 and PC3. (A) BMV-Cy5 in PNT2, (B) BMV-Cy5 in PC3 (C) BMV-
SM(PEG)24-P1 in PNT2, (D) BMV-SM(PEG)24-P1 in PC3, (E) BMV-SM(PEG)24-P2 in PNT2, (F) BMV-
SM(PEG)24-P2 in PC3. The nucleus is stained in blue (DAPI) and the cell membrane in green (WGA). The 
VNPs are in red and can be located with the white arrows. The scale bar represents 10 µm.  
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Figure 4.29: Micrograph of passive and active uptake of BMV-Cy5 conjugated with Peptide 1 and 2 and 
crosslinker SM(PEG)24, uptake into three different prostate cells. (A) BMV-SM(PEG)24-P1 in PNT2, (B) BMV-
SM(PEG)24-P2 in PNT2, (C) BMV-SM(PEG)24-P1 in VCaP, (D) BMV-SM(PEG)24-P2 in VCaP, (E) BMV-
SM(PEG)24-P1 in PC3, (F) BMV-SM(PEG)24-P2 in PC3. The nucleus is stained in blue (DAPI) and the cell 
membrane in green (WGA). The VNPs are in red and can be located with the white arrows. The scale bar 
represents 10 µm. 
A B 
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Chapter 5 
Conclusion 
The aim of this study was to modify an icosahedral plant virus, Brome mosaic virus, with a 
fluorescent molecule and a targeting peptide. This VNP was then assessed for its targeting 
efficiency in normal and cancerous prostate cell lines. 
BMV was purified from infected N. benthamiana plants with excellent yield in order to 
proceed with the conjugation methods. The fluorescent labeling of Cy5 to the glutamic acid 
residues on the surface of the BMV coat protein was successful. A consistent number of 50 
fluorescent molecules could be bound per conjugation. Both peptides, PKRGFQD-C and 
SNTRVAP-C, could be conjugated to the lysine residues using the SM(PEG)24 crosslinker. 
This was confirmed with SDS-PAGE and MALDI-TOF MS analysis. SM(PEG)24 was the only 
crosslinker that provided efficient binding of the peptide, as confirmed with SDS-PAGE. A 
problem arose when we initially attempted to first conjugate the fluorescent molecule, and 
then use the fluorescently-labeled BMV for the peptide conjugation. In this case the peptide 
conjugation was unsuccessful and upon examination of the amino acid composition on the 
coat protein, we concluded that there might be interference from the glutamic acids when 
the fluorescent molecule is bound. 
We then proceeded to conjugate both the fluorescent molecules and peptides 
simultaneously to the lysine residues, and this was successful. In spite of competition for 
binding sites between fluorescent molecules and peptides for the same amino acid, there 
was still a high number of fluorescent molecules bound. This suggests that the 180 reactive 
amino acids that were identified (Wen et al., 2012a) is sufficient for conjugation of both a 
fluorescent molecule and a targeting peptide. This reaction was only performed twice and 
therefore a future prospect will be to repeat the experiments. We could not however analyze 
the samples using MALDI-TOF MS due to unforeseen technical issues which rendered the 
equipment unavailable at this time. Future experiments to quantitatively analyze whether the 
peptides are bound are planned. 
The uptake using both peptides into the androgen-independent cell line, PC3, was very high. 
Peptide 1 had an uptake of 75% and Peptide 2 was 95%, which is better than expected. We 
expected the VNPs to be targeted to androgen-independent cell lines as the peptides are 
specific for the receptors (Mandelin et al., 2015). The uptake in the androgen-dependent cell 
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line, VCaP, was also high, but it was lower than the normal prostate cells, PNT2. The 
efficient uptake into the normal prostate cells are not ideal as we would like to limit the uptake 
to cancerous prostate cells. The normal prostate cells may also contain the receptors as this 
has not been evaluated before, which would explain the high internalization. The uptake into 
the PC3 cells was however significantly more than for PNT2, and we would hope that the 
VNPs will preferentially enter the cells with the targeted receptors on the surface. The 
specificity of the peptides to control cell lines other than sarcoma have not been investigated 
(Mandelin et al., 2015) and therefore a future prospect will be to assess the uptake in 
outgroup cell lines, both normal and other cancerous, to validate whether the uptake will be 
similar for all other cells or if it is just higher in prostate cells. This may allow us to limit the 
VNPs to only prostate cells. 
Further future studies will include attaching a drug molecule, Doxorubicin, to the VNPs. This 
will be assessed with cell death assays to validate whether drug is successfully delivered to 
the cancer cell lines. 
In conclusion, this study proved that BMV is a valuable candidate as a VNP for prostate 
cancer. It can be purified with ease from N. benthamiana with high yield and it can be 
modified with a fluorescent label and targeting peptides using the lysine residues. The 
uptake of the VNPs into androgen-independent cell lines is also remarkable. 
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